KR20150102449A - Composition comprising an extract of crude drug for treating and improving skin-aging or skin trouble - Google Patents
Composition comprising an extract of crude drug for treating and improving skin-aging or skin trouble Download PDFInfo
- Publication number
- KR20150102449A KR20150102449A KR1020140024319A KR20140024319A KR20150102449A KR 20150102449 A KR20150102449 A KR 20150102449A KR 1020140024319 A KR1020140024319 A KR 1020140024319A KR 20140024319 A KR20140024319 A KR 20140024319A KR 20150102449 A KR20150102449 A KR 20150102449A
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- extract
- licorice
- acid
- skin
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 230000009759 skin aging Effects 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title description 5
- 229940079593 drug Drugs 0.000 title description 4
- 239000002537 cosmetic Substances 0.000 claims abstract description 35
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 54
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 53
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 53
- 229940010454 licorice Drugs 0.000 claims description 53
- 241000202807 Glycyrrhiza Species 0.000 claims description 49
- 239000006210 lotion Substances 0.000 claims description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000006071 cream Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 235000016709 nutrition Nutrition 0.000 claims description 11
- 241000723353 Chrysanthemum Species 0.000 claims description 10
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 9
- 239000000118 hair dye Substances 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 7
- 230000035764 nutrition Effects 0.000 claims description 6
- 239000000344 soap Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 229940069445 licorice extract Drugs 0.000 claims description 4
- 239000000865 liniment Substances 0.000 claims description 4
- 229940040145 liniment Drugs 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 235000015927 pasta Nutrition 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 241000195940 Bryophyta Species 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000008266 hair spray Substances 0.000 claims description 2
- 239000004922 lacquer Substances 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 239000002274 desiccant Substances 0.000 claims 1
- 239000003051 hair bleaching agent Substances 0.000 claims 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract description 4
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract description 4
- 241000037740 Coptis chinensis Species 0.000 abstract description 3
- 241000576429 Forsythia suspensa Species 0.000 abstract description 3
- -1 ABTS radical cation Chemical class 0.000 description 64
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 44
- 230000000694 effects Effects 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 37
- 239000000523 sample Substances 0.000 description 34
- 238000002474 experimental method Methods 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 30
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 29
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 28
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 25
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 24
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 24
- 229960001340 histamine Drugs 0.000 description 22
- 230000003078 antioxidant effect Effects 0.000 description 21
- 238000005259 measurement Methods 0.000 description 21
- 102100040247 Tumor necrosis factor Human genes 0.000 description 20
- 235000019441 ethanol Nutrition 0.000 description 20
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 102000019197 Superoxide Dismutase Human genes 0.000 description 15
- 108010012715 Superoxide dismutase Proteins 0.000 description 15
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 108090001007 Interleukin-8 Proteins 0.000 description 13
- 102000004890 Interleukin-8 Human genes 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 229940088594 vitamin Drugs 0.000 description 10
- 229930003231 vitamin Natural products 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 10
- 239000011782 vitamin Substances 0.000 description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 9
- 230000003266 anti-allergic effect Effects 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000003020 moisturizing effect Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000000686 essence Substances 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 229920001296 polysiloxane Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 6
- 241000234282 Allium Species 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 241001474374 Blennius Species 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- ACXGEQOZKSSXKV-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC(O)=O ACXGEQOZKSSXKV-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 235000013772 propylene glycol Nutrition 0.000 description 6
- 229960004063 propylene glycol Drugs 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 5
- 241000186427 Cutibacterium acnes Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 241000194019 Streptococcus mutans Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000004042 decolorization Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000001023 inorganic pigment Substances 0.000 description 5
- XDOFQFKRPWOURC-UHFFFAOYSA-N iso-octadecanoic acid Natural products CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 4
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 4
- 108010053835 Catalase Proteins 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- 241001165494 Rhodiola Species 0.000 description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 229940079877 pyrogallol Drugs 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960000984 tocofersolan Drugs 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- 239000002076 α-tocopherol Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 3
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 235000019482 Palm oil Nutrition 0.000 description 3
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000002280 amphoteric surfactant Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229960005150 glycerol Drugs 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000021995 interleukin-8 production Effects 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 229940089456 isopropyl stearate Drugs 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000012860 organic pigment Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002540 palm oil Substances 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940083618 sodium nitroprusside Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 238000003026 viability measurement method Methods 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- PYJQLUORHGLSGS-UHFFFAOYSA-N 16-methylheptadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C PYJQLUORHGLSGS-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 2
- 235000006008 Brassica napus var napus Nutrition 0.000 description 2
- 240000000385 Brassica napus var. napus Species 0.000 description 2
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000088415 Raphanus sativus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- 235000013932 Rosa davurica Nutrition 0.000 description 2
- 241000675183 Rosa davurica Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- YRXGUZPUZBCGST-UHFFFAOYSA-N [2-(hydroxymethoxy)phenyl]-phenylmethanone Chemical compound OCOC1=CC=CC=C1C(=O)C1=CC=CC=C1 YRXGUZPUZBCGST-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 238000006701 autoxidation reaction Methods 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 229910000423 chromium oxide Inorganic materials 0.000 description 2
- 230000011382 collagen catabolic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- RAPXDXJBAYUBHI-UHFFFAOYSA-N decyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCCCCCC RAPXDXJBAYUBHI-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229940068052 ginkgo biloba extract Drugs 0.000 description 2
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- PIUVNPNBPWVVKZ-UHFFFAOYSA-N octadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC PIUVNPNBPWVVKZ-UHFFFAOYSA-N 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RLUCXJBHKHIDSP-UHFFFAOYSA-N propane-1,2-diol;propanoic acid Chemical compound CCC(O)=O.CC(O)CO RLUCXJBHKHIDSP-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- DEQUKPCANKRTPZ-UHFFFAOYSA-N (2,3-dihydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1O DEQUKPCANKRTPZ-UHFFFAOYSA-N 0.000 description 1
- BOCBOJPUWMTAJB-UHFFFAOYSA-N (2-butylphenyl) 2-hydroxybenzoate Chemical compound CCCCC1=CC=CC=C1OC(=O)C1=CC=CC=C1O BOCBOJPUWMTAJB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102100027833 14-3-3 protein sigma Human genes 0.000 description 1
- 108050008974 14-3-3 protein sigma Proteins 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- SAMYFBLRCRWESN-UHFFFAOYSA-N 16-methylheptadecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C SAMYFBLRCRWESN-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 1
- ZMXUPLNMYABPEB-UHFFFAOYSA-N 2-[[2-(dodecanoylamino)acetyl]amino]acetic acid Chemical compound CCCCCCCCCCCC(=O)NCC(=O)NCC(O)=O ZMXUPLNMYABPEB-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- HTNFLUQQANUSLR-UHFFFAOYSA-N 2-octanoyloxyethyl octanoate Chemical compound CCCCCCCC(=O)OCCOC(=O)CCCCCCC HTNFLUQQANUSLR-UHFFFAOYSA-N 0.000 description 1
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- SDZHIRPZKXFSBX-UHFFFAOYSA-N 3-(dodecanoylamino)propanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCC(=O)NCCC(O)=O SDZHIRPZKXFSBX-UHFFFAOYSA-N 0.000 description 1
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical class C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- BCNMHJYHRSTPJY-UHFFFAOYSA-N 8-methylnonyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC(C)C BCNMHJYHRSTPJY-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- QVNCZVPOUKXBBQ-UHFFFAOYSA-N C(CCCCCCCCCCC)(=O)OCCCCCCCCCCCC.[Ca] Chemical compound C(CCCCCCCCCCC)(=O)OCCCCCCCCCCCC.[Ca] QVNCZVPOUKXBBQ-UHFFFAOYSA-N 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000018 Chemokine CCL2 Human genes 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 235000008597 Diospyros kaki Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102100033167 Elastin Human genes 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- PYVHTIWHNXTVPF-UHFFFAOYSA-N F.F.F.F.C=C Chemical compound F.F.F.F.C=C PYVHTIWHNXTVPF-UHFFFAOYSA-N 0.000 description 1
- 108010030229 Fibrillin-1 Proteins 0.000 description 1
- 102100031509 Fibrillin-1 Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 241001198924 Forsythia koreana Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 101710128038 Hyaluronan synthase Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 101150109636 Inos gene Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWUCIPXNTHJNJC-UHFFFAOYSA-N Matairesinoside Natural products COc1cc(CC2C(Cc3ccc(OC4OC(CO)C(O)C(O)C4O)c(OC)c3)CCC2=O)ccc1O PWUCIPXNTHJNJC-UHFFFAOYSA-N 0.000 description 1
- AAGCATAPYOEULE-UHFFFAOYSA-N Matairesinoside aglycone Natural products C1=C(O)C(OC)=CC(CC2C(C(=O)OC2)CC=2C=C(OC)C(OC3C(C(O)C(O)C(CO)O3)O)=CC=2)=C1 AAGCATAPYOEULE-UHFFFAOYSA-N 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 239000004640 Melamine resin Substances 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GKXJWSZPLIKUPS-IUNAMMOKSA-N N-[(2Z,6Z)-2,6-bis(hydroxyimino)cyclohexylidene]hydroxylamine Chemical compound O\N=C1\CCC\C(=N\O)C1=NO GKXJWSZPLIKUPS-IUNAMMOKSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- KQHKSGRIBYJYFX-UHFFFAOYSA-J Ponceau S Chemical compound [Na+].[Na+].[Na+].[Na+].Oc1c(cc2cc(ccc2c1N=Nc1ccc(cc1S([O-])(=O)=O)N=Nc1ccc(cc1)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O KQHKSGRIBYJYFX-UHFFFAOYSA-J 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241001414989 Thysanoptera Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WUBKCBOQNXUQDU-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone Chemical compound OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 WUBKCBOQNXUQDU-UHFFFAOYSA-N 0.000 description 1
- SVRHJWALMLOXMI-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone;sodium Chemical compound [Na].OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 SVRHJWALMLOXMI-UHFFFAOYSA-N 0.000 description 1
- KSHPUQQHKKJVIO-UHFFFAOYSA-N [Na].[Zn] Chemical compound [Na].[Zn] KSHPUQQHKKJVIO-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 239000001518 benzyl (E)-3-phenylprop-2-enoate Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- NGHOLYJTSCBCGC-QXMHVHEDSA-N benzyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-QXMHVHEDSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- JHXKRIRFYBPWGE-UHFFFAOYSA-K bismuth chloride Chemical compound Cl[Bi](Cl)Cl JHXKRIRFYBPWGE-UHFFFAOYSA-K 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- FCQAMVZGVMHDFT-UHFFFAOYSA-N butane-1,4-diol;propane-1,2,3-triol Chemical compound OCCCCO.OCC(O)CO FCQAMVZGVMHDFT-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- AGNCRIYGRWNVIF-UHFFFAOYSA-N calcium;2-(dodecanoylamino)acetic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCC(O)=O AGNCRIYGRWNVIF-UHFFFAOYSA-N 0.000 description 1
- CEGYXKLZALIAEI-UHFFFAOYSA-N calcium;2-(dodecanoylamino)ethanesulfonic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCCS(O)(=O)=O CEGYXKLZALIAEI-UHFFFAOYSA-N 0.000 description 1
- YEFORLIOCBRMFS-UHFFFAOYSA-N calcium;2-(hexadecanoylamino)ethanesulfonic acid Chemical compound [Ca].CCCCCCCCCCCCCCCC(=O)NCCS(O)(=O)=O YEFORLIOCBRMFS-UHFFFAOYSA-N 0.000 description 1
- HOQGRRFKKLWWOO-UHFFFAOYSA-N calcium;3-(dodecanoylamino)propanoic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCCC(O)=O HOQGRRFKKLWWOO-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- NGHOLYJTSCBCGC-UHFFFAOYSA-N cis-cinnamic acid benzyl ester Natural products C=1C=CC=CC=1C=CC(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- WVWRBUIUZMBLNI-UHFFFAOYSA-N decyl octanoate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC WVWRBUIUZMBLNI-UHFFFAOYSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940031769 diisobutyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N dodecanoic acid ethyl ester Natural products CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000002044 guayabota nspero Nutrition 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- FPMPNVIMFPEKRN-UHFFFAOYSA-N hexyl 16-methylheptadecanoate Chemical compound CCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C FPMPNVIMFPEKRN-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 239000010015 huanglian Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 229940113915 isostearyl palmitate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- AAGCATAPYOEULE-LHHMAMHXSA-N matairesinoside Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)=C1 AAGCATAPYOEULE-LHHMAMHXSA-N 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LAQFLZHBVPULPL-UHFFFAOYSA-N methyl(phenyl)silicon Chemical compound C[Si]C1=CC=CC=C1 LAQFLZHBVPULPL-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- NNSWOABHNWRKDR-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine;octadecanoic acid Chemical compound CCN(CC)CCN.CCCCCCCCCCCCCCCCCC(O)=O NNSWOABHNWRKDR-UHFFFAOYSA-N 0.000 description 1
- RVRFYZGKUZFYAH-UHFFFAOYSA-N n',n'-dimethylpropane-1,3-diamine;octadecanoic acid Chemical compound CN(C)CCCN.CCCCCCCCCCCCCCCCCC(O)=O RVRFYZGKUZFYAH-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N n-alpha-eicosene Natural products CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- GQEZCXVZFLOKMC-UHFFFAOYSA-N n-alpha-hexadecene Natural products CCCCCCCCCCCCCCC=C GQEZCXVZFLOKMC-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LYKRPDCJKSXAHS-UHFFFAOYSA-N phenyl-(2,3,4,5-tetrahydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1O LYKRPDCJKSXAHS-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940116422 propylene glycol dicaprate Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940077082 red pepper extract Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical class NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- SZEMGTQCPRNXEG-UHFFFAOYSA-M trimethyl(octadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C SZEMGTQCPRNXEG-UHFFFAOYSA-M 0.000 description 1
- 229940113165 trimethylolpropane Drugs 0.000 description 1
- APVVRLGIFCYZHJ-UHFFFAOYSA-N trioctyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCC)CC(=O)OCCCCCCCC APVVRLGIFCYZHJ-UHFFFAOYSA-N 0.000 description 1
- COXJMKGEQAWXNP-UHFFFAOYSA-N tris(14-methylpentadecyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCCCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCCCCCCCC(C)C)CC(=O)OCCCCCCCCCCCCCC(C)C COXJMKGEQAWXNP-UHFFFAOYSA-N 0.000 description 1
- AGBVGLJAIGBYAD-UHFFFAOYSA-N tris(2-methylpropyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)COC(=O)CC(O)(C(=O)OCC(C)C)CC(=O)OCC(C)C AGBVGLJAIGBYAD-UHFFFAOYSA-N 0.000 description 1
- RHNXTZDKMRCKKT-UHFFFAOYSA-N tris(6-methylheptyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCOC(=O)CC(O)(C(=O)OCCCCCC(C)C)CC(=O)OCCCCCC(C)C RHNXTZDKMRCKKT-UHFFFAOYSA-N 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 감초, 황련 또는 연교 추출물을 유효성분으로 함유하는 피부노화, 또는 피부염 치료 및 개선용 피부외용 약학조성물 및 화장료 조성물에 관한 것이다.The present invention relates to a dermatological pharmaceutical composition and a cosmetic composition for treating or ameliorating skin aging or dermatitis containing licorice, chrysanthemum or licorice extract as an active ingredient.
[문헌 1] Voegeli, R. 1996. Elastase and typtase determination on human skin surface. Cosmetic &Toiletries. 111, 51-58 [1] Voegeli, R. 1996. Elastase and typing determination on human skin surface. Cosmetic & Toiletries. 111, 51-58
[문헌 2] Kim HH, Cho S, Lee S, Kim KH, Cho KH, Eun HC, Chung JH., Photoprotective and anti-skin-aging effects of eicosapentaenoic acid in human skin in vivo. J Lipid Res . 47(5),pp.921-30, 2006; [2] Kim HH, Cho S, Lee S, Kim KH, Cho KH, Eun HC, Chung JH, Photoprotective and anti-skin-aging effects of eicosapentaenoic acid in human skin in vivo. J Lipid Res . 47 (5) , pp.921-30, 2006;
[문헌 3] Medina A, Ghaffari A, Kilani RT, Ghahary A., The role of stratifin in fibroblast-keratinocyte interaction. Mol Cell Biochem . 305(1-2), pp.255-64, Review, 2007.[3] Medina A, Ghaffari A, Kilani RT, Ghahary A., The role of stratifin in fibroblast-keratinocyte interaction. Mol Cell Biochem . 305 (1-2) , pp. 255-64, Review, 2007.
[문헌 4] Wang XJ, Han G, Owens P, Siddiqui Y, Li AG., Role of TGF beta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc . 11(1), pp.112-7, Review, 2006; [4] Wang XJ, Han G, Owens P, Siddiqui Y, Li AG., Role of TGF beta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc . 11 (1) , pp. 112-7, Review, 2006;
[문헌 5] Traidl-Hoffmann C, MI, Ring J, Behrendt H., Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: Implications for anti-inflammatory activity of antihistamines. Int Arch Allergy Immunol . 140(4), pp.315-20, 2006 [5] Traidl-Hoffmann C, MI, Ring J, Behrendt H., Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: Implications for anti-inflammatory activity of antihistamines. Int Arch Allergy Immunol . 140 (4) , pp.315-20, 2006
[문헌 6] Cannon JG, Tatro JB, Reichlin S, Dinarello CA., Alpha melanocyte stimulating hormone inhibits immunostimulatory and inflammatory actions of interleukin 1. J Immunol . 137(7), pp.2232-6, 1986 [6] Cannon JG, Tatro JB, Reichlin S, Dinarello CA., Alpha melanocyte stimulating hormone inhibits immunostimulatory and inflammatory actions of
[문헌 7] Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T., Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol . 164(12), pp.6174-9, 2000; [7] Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T., Monocyte chemoattractant protein-1 enhancer gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol . 164 (12) , pp.6174-9, 2000;
[문헌 8] Dai G, Freudenberger T, Zipper P, Melchior A, Grether-Beck S, Rabausch B, de Groot J, Twarock S, Hanenberg H, Homey B, Krutmann J, Reifenberger J, Fischer JW., Chronic ultraviolet B irradiation causes loss of hyaluronic acid from mouse dermis because of down-regulation of hyaluronic acid synthases. Am J Pathol . 171(5), pp.1451-61, 2007 [Patent Literature 8] Dai G, Freudenberger T, Zipper P, Melchior A, Grether-Beck S, Rabausch B, de Groot J, Twarock S, Hanenberg H, Homey B, Krutmann J, Reifenberger J, Fischer JW., Chronic ultraviolet B Hyaluronic acid synthase is the down-regulation of hyaluronic acid synthases. Am J Pathol . 171 (5) , pp.1451-61, 2007
[문헌 9] 정보섭, 신민교, 도해향약대사전, 영림사, pp684-687, 1998 [Literature 9] Information Supervision, Shin Min-gyo, Dae-hae Encyclopedia, Young Lim, pp684-687, 1998
[문헌 10] 정보섭외 도해향약대사전, 영림사, p491-493, 1998년 [Reference 10] Metaphorical analysis of information and communication, Yeonglim, p491-493, 1998
[문헌 11] 정보섭외 도해향약대사전, 영림사, p974-975, 1998년[Literature 11] Information on the Interview with Professor Lee, Young Lim, p974-975, 1998
[문헌 12] Blois MS. Antioxidant determination by the use of a stable free radical. Nature. 1958;26:1199~1120[Literature 12] Blois MS. Antioxidant determination by the use of a stable free radical. Nature . 1958; 26: 1199-1120
[문헌 13] Amariwicz, R., Naczk, M., Shahidi, F. (2000). Antioxidant activity of various fractions of non-tannic phenolics of canola hulls. J. of Agric Food Chem. 48: 2755-2759[문헌 14]Roberta, R.E., Pellegrini, N., Anna, P., Ananth, P., Yang, M., Catherine, R.E.,(1999). Antioxidant activity applying an improved ABTS radical cation decolorization assay. J. of Free Radical Biology & Medicine. 26: 1231-1237[Document 13] Amariwicz, R., Naczk, M., Shahidi, F. (2000). Antioxidant activity of various fractions of non-tannic phenolics of canola hulls. J. of Agric Food Chem. 48: 2755-2759 [Literature 14] Roberta, R. E., Pellegrini, N., Anna, P., Ananth, P., Yang, M., Catherine, R. E., (1999). Antioxidant activity was improved by ABTS radical cation decolorization assay. J. of Free Radical Biology & Medicine. 26: 1231-1237
[문헌 15] Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur . J. Biochem . 1974;47:469~474[Document 15] Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur . J. Biochem . 1974; 47: 469-474
[문헌 16] Pryor WA. Oxy-radicals and related species : their formation, lifetimes, and reactions. Annu . Rev . Physiol . 1986;48:657~667[Literature 16] Pryor WA. Oxy-radicals and related species: their formation, lifetimes, and reactions. Annu . Rev. Physiol . 1986; 48: 657-667
[문헌 17] Greenstock CL. Radiation and aging : free radical damage, biological response and possible antioxidant intervention. Med . Hypotheses . 1993;41(5):473~482[Literature 17] Greenstock CL. Radiation and aging: free radical damage, biological response and possible antioxidant intervention. Med . Hypotheses . 1993; 41 (5): 473-482
[문헌 18] Marcocci L., Maguire J. J., Droylefaix M. T. and Packer L. : The Nitric Oxide Scavenging Properties of Ginkgo Biloba Extract EGb 761. Biochemical and Biophysical Research Communications. 201, 15, 748-755, 1994[Literature 18] Marcocci L., Maguire J. J., Droylefaix M. T. and Packer L.: The Nitric Oxide Scavenging Properties of Ginkgo Biloba Extract EGb 761. Biochemical and Biophysical Research Communications. 201, 15, 748-755, 1994
[문헌 19] Sreejayan, N. and Rao, M. NA. : Nitric oxide scavenging by curcuminoids. Journal of Pharmacy and Pharmacology, 49, 105-107, 1997[Literature 19] Sreejayan, N. and Rao, M. NA. : Nitric oxide scavenging by curcuminoids. Journal of Pharmacy and Pharmacology, 49, 105-107, 1997
[문헌 20] Han HK, Choi SS, Shin JC< Chung HS(2007) A study on single oral dose toxicity of highly-developed anthocyanin-pigmented rice varieties. J. Kor. Soc. Food Sci. Nutr. 36:527-533[20] Han HK, Choi SS, Shin JC <Chung HS (2007) A study on single oral dose toxicity of highly anthocyanin-pigmented rice varieties. J. Kor. Soc. Food Sci. Nutr. 36: 527-533
[문헌 21] Kim SJ, Lee EJ, Song YS, Jeong HJ, Le KM, Kim HR, Chae HJ, Shin TY, Kim YK, Hong SH, Kim HM. Cheongyol saseuptang inhibits production of TNF-alpha, IL-6 and IL-8 as well as NF-kappa B activation in human mast cells. J Ethnopharmacol. 2005; 97: 83-8[21] Kim SJ, Lee EJ, Song YS, Jeong HJ, Le KM, Kim HR, Chae HJ, Shin TY, Kim YK, Hong SH, Kim HM. Cheongyol saseuptang inhibits production of TNF-alpha, IL-6 and IL-8 as well as NF-kappa B activation in human mast cells. J Ethnopharmacol. 2005; 97: 83-8
[문헌 22] Kim HM, Park YA, Lee EJ, Shin TY. Inhibition of immediate-type allergic reation by Rosa davurica Pall. In a murine model. J Ethnophamacol. 1999; 67: 53-60
[22] Kim HM, Park YA, Lee EJ, Shin TY. Inhibition of immediate-type allergic reation by Rosa davurica Pall. In a murine model. J Ethnophamacol. 1999; 67: 53-60
현대인들은 자외선, 스트레스 등의 여러 가지 내외적인 요인에 의해 각종 피부 트러블 유발로 기미, 주근깨, 피부 색소 침착 등의 피부 노화 현상을 촉진한다(Voegeli, R. 1996. Elastase and typtase determination on human skin surface. Cosmetic &Toiletries. 111, 51-58.). Modern people promote skin aging phenomena such as spots, freckles and skin pigmentation by inducing various skin troubles due to various internal and external factors such as ultraviolet rays and stress (Voegeli, R. 1996. Elastase and typing determination on human skin surface. Cosmetic & Toiletries. 111, 51-58.).
환경의 파괴로 인한 자외선 증가 및 각종 산화성 물질의 증가는 피부 손상과 단백질의 합성능 저하를 유발할 수 있다. 이러한 피부 세포의 손상이나 기능 저하는 피부 탄력의 감소, 피부 주름살의 증가, 기미와 주근깨 생성 등 피부 미용에 치명적인 현상들을 유발한다. 피부 탄력성은 진피조직의 콜라겐(collagen), 엘라스틴(elastin), 히알루론산(hyaluronic acid) 등에 의해 유지되며, 콜라겐(collagen)을 합성하는 섬유아세포(fibroblast)는 핵심적인 역할을 한다(1). 섬유아세포 기능은 각종 성장인자(growth factor) 뿐만 아니라 케라티노사이트(keratinocyte)나 멜라노사이트(melanocyte)와 같은 피부 세포들에서 분비되는 싸이토카인(cytokine)에 의해서도 조절된다(2-3). 정상적인 상태에서 유리되는 케라티노사이트의 TGF-β, TβRII, SGad3는 피부 섬유아세포(dermal fibroblast)로 부터 프로콜라겐(procollagen), 피브릴린(fibrillin-1), tropoelastin의 발현을 증가시켜 콜라겐 생성을 증가시키며, MMPs의 발현을 억제하여 콜라겐 분해를 억제하는 것으로 보고되었다(Kim HH, Cho S, Lee S, Kim KH, Cho KH, Eun HC, Chung JH., Photoprotective and anti-skin-aging effects of eicosapentaenoic acid in human skin in vivo. J Lipid Res. 47(5),pp.921-30, 2006; Medina A, Ghaffari A, Kilani RT, Ghahary A., The role of stratifin in fibroblast-keratinocyte interaction. Mol Cell Biochem . 305(1-2), pp.255-64, Review, 2007.). The increase of ultraviolet rays and the increase of various oxidizing substances due to the destruction of the environment can cause skin damage and deterioration of the total performance of proteins. Such damage or deterioration of the skin cells causes a decrease in skin elasticity, an increase in skin wrinkles, and a lethal phenomenon in skin cosmetics such as stain and freckle formation. Skin elasticity is maintained by collagen, elastin, hyaluronic acid, and fibroblast, which synthesizes collagen (1). Fibroblast function is regulated not only by various growth factors but also by cytokines secreted from skin cells such as keratinocytes and melanocytes (2-3). TGF-β, TβRII, and SGad3 of keratinocytes liberated under normal conditions increase the expression of procollagen, fibrillin-1, and tropoelastin from dermal fibroblasts, resulting in collagen production , And suppression of collagen degradation by inhibiting the expression of MMPs (Kim HH, Cho S, Lee S, Kim KH, Cho KH, Eun HC and Chung JH, Photoprotective and anti-skin-aging effects of eicosapentaenoic acid .. acid in human skin in vivo J Lipid Res 47 (5), pp.921-30, 2006;. Medina A, Ghaffari A, Kilani RT, Ghahary A., The role of stratifin in fibroblast-keratinocyte interaction Mol Cell Biochem . 305 (1-2) , pp. 255-64, Review, 2007.).
UV에 의해 케라티노사이트가 손상되면 TGF-β(transforming growth factor) 외에도 TNF-α(tumor necrosis factor), PGE2 (prostaglandin E2), α-MSH(melanocyte stimulating hormone), GSF(granulocyte stimulating factor), IL-1(interleukin-1), IL-6, IL-8, IL-10 등의 유리가 유발한다(Wang XJ, Han G, Owens P, Siddiqui Y, Li AG., Role of TGF beta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc . 11(1), pp.112-7, Review, 2006; Traidl-Hoffmann C, MI, Ring J, Behrendt H., Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: Implications for anti-inflammatory activity of antihistamines. Int Arch Allergy Immunol. 140(4), pp.315-20, 2006.). 이중 α-MSH와 PGE2는 멜라노사이트를 자극하여 멜라닌 생성을 촉진하여, 이 멜라닌은 피부 세포의 항산화 작용을 증강시켜 피부세포가 자외선으로 인해 손상되는 것을 방어하게 한다(Cannon JG, Tatro JB, Reichlin S, Dinarello CA., Alpha melanocyte stimulating hormone inhibits immunostimulatory and inflammatory actions of interleukin 1. J Immunol . 137(7), pp.2232-6, 1986.). In addition to TGF-beta (transforming growth factor), tumor necrosis factor (TNF-alpha), PGE 2 (prostaglandin E 2 ), α-MSH (melanocyte stimulating hormone), GSF (granulocyte stimulating factor), IL-1 (interleukin-1), IL-6, IL-8 and IL-10 XJ, Han G, Owens P, Siddiqui Y, Li AG., Role of TGF beta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc . 11 (1) , pp. 112-7, Review, 2006; Traidl-Hoffmann C, MI, Ring J, Behrendt H., Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: Implications for anti-inflammatory activity of antihistamines. Int Arch Allergy Immunol. 140 (4) , pp.315-20, 2006.). Both α-MSH and PGE 2 stimulate melanocytes to promote melanogenesis, which enhances the antioxidant action of skin cells and prevents skin cells from being damaged by ultraviolet rays (Cannon JG, Tatro JB, Reichlin S, Dinarello CA., Alpha melanocyte stimulating hormone inhibits immunostimulatory and inflammatory actions of
IL-1, TNF-α(tumor necrosis factor) 등은 fibroblast에 작용하여 procollagen 발현을 억제하며, MMP-1 (martrix metalloproteinase-1), MMP-2, MMP-3, 히알루로니다아제(hyaluronidase)등의 활성을 증가시켜 콜라겐 분해를 촉진하게 된다(Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T., Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol . 164(12), pp.6174-9, 2000; Dai G, Freudenberger T, Zipper P, Melchior A, Grether-Beck S, Rabausch B, de Groot J, Twarock S, Hanenberg H, Homey B, Krutmann J, Reifenberger J, Fischer JW., Chronic ultraviolet B irradiation causes loss of hyaluronic acid from mouse dermis because of down-regulation of hyaluronic acid synthases. Am J Pathol. 171(5), pp.1451-61, 2007.). IL-1 and TNF-α (tumor necrosis factor) act on fibroblasts to inhibit procollagen expression and inhibit MMP-1 (martrix metalloproteinase-1), MMP-2, MMP-3, hyaluronidase And the collagen degradation is accelerated (Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T., Monocyte chemoattractant protein-1 enhancer gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL .. -1 alpha loop J Immunol 164 (12), pp.6174-9, 2000; Dai G, Freudenberger T, Zipper P, Melchior A, Grether-Beck S, Rabausch B, de Groot J, Twarock S, Hanenberg H , Homey B, Krutmann J, Reifenberger J, Fischer JW., Chronic ultraviolet B irradiation causes loss of hyaluronic acid from mouse dermis because of down-regulation of hyaluronic acid synthases. Am J Pathol. 171 (5) , pp.1451-61 , 2007.).
또한, UV에 의해 직접적으로 섬유아세포 (fibroblast)가 상해를 받는 경우에도 콜라겐 관련 유전자는 억제되고 분해에 관련되는 MMPs류 발현은 촉진되어 주름살은 증가하게 된다. 따라서, 진피 섬유아세포 (dermal fibroblast)의 증식과 콜라겐 합성을 증가시키거나, MMPs을 억제하는 것은 주름살을 생성을 억제하는 수단이 될 수 있다.In addition, even if fibroblast is directly injured by UV, the collagen-related gene is suppressed and the expression of MMPs related to degradation is promoted and the wrinkles are increased. Thus, increasing the proliferation and collagen synthesis of dermal fibroblasts, or inhibiting MMPs, may be a means of inhibiting the formation of wrinkles.
감초(甘草, Glycyrrhizae Radix)는 콩과(Leguminosae)에 속하는 다년생 초본식물로 시베리아, 몽고 및 중국의 내몽고(內蒙古), 감숙(甘肅) 등 북부 지방에서 자라며, 주성분은 트리테르펜 사포닌(triterpene saponins), 글리시렉틱 산(glycyrrhetic acid), 플라보노이드(flavonoids), 이소플라보노이드(isoflavonoids), 쿠메스탄 유도체(cumestan derivatives), 하이드록시코마린(hydroxycoumarins), 스테로이드(steroids), 발라틸 오일(volatile oil) 등으로, 해독작용, 간염, 두드러기, 피부염, 습진, 진해·거담, 근육이완, 이뇨작용, 항염작용 등이 있다고 알려져 있다. 감초는 콩과(Leguminosae)에 속하는 감초(Glycyrrhiza uralensis) 및 동속식물의 근경으로서, 그 성분으로는 글리시리진(glycyrrhizin), 리퀴리티게닌(liquiritigenin), 이소리퀴리티게닌(isoliquiritigenin), 네오이소리퀴리티게닌(neoisoliquiritigenein), 등을 함유하고, 해독작용, 진해거담작용, 항알레르기작용, 위액분비억제작용 등의 효능이 알려져 있다 (정보섭, 신민교, 도해향약대사전, 영림사, pp684-687, 1998).Glycyrrhizae Radix is a perennial herbaceous plant belonging to the family Leguminosae and grows in the northern regions of Siberia, Mongolia and Inner Mongolia and Gansu in China. Its main components are triterpene saponins, Glycyrrhetic acid, flavonoids, isoflavonoids, cumestan derivatives, hydroxycoumarins, steroids, volatile oil, and the like. , Detoxification action, hepatitis, urticaria, dermatitis, eczema, Jinhae and geomung, muscle relaxation, diuretic action, and anti-inflammatory action. Licorice is a root of licorice belonging to Leguminosae (Glycyrrhiza uralensis) and the relative plants and its components are glycyrrhizin, liquiritigenin, isoliquiritigenin, (Neoisoliquiritigenein), and the detoxification effect, the Jinhae genotyping effect, the antiallergic action, and the gastric secretion inhibitory action are known (Lee, Seong-min, Shin, Min-gyo).
황련 (Coptidis chinensis Radix)는 미나이아재비과 속하는 다년생 초본인 황련의 근경을 건조한 것으로, 베르베린(berberine), 콥티신(coptisine), 팔마틴(palmatine), 야테로리진(jateorrhizine) 등의 성분을 함유하고 있고, 하리, 구토, 살충, 소독 등의 약리작용이 있다고 알려져 있다.(정보섭외 도해향약대사전, 영림사, p491-493, 1998년). Coptidis chinensis Radix is a dried perennial rootstock of perennial herbaceous perennial herb and belongs to berberine, coptisine, palmatine, and jaterorrhizine. , Hari, vomiting, insecticide, disinfection, etc. (The information dictionary of the information and the survey, Yeonglim, p491-493, 1998).
연교는 물부레나무과 속하는 다년생 초본인 개나리 (Forsythia koreana)의 과실을 건조한 것으로, 포루톨(forsythol), 마타리레노시드(matairesinoside), 올레아놀리산 (oleanolic acid), 알칼로이드(alkaloid) 등의 성분을 함유하고 있다고 알려져 있다.(정보섭외 도해향약대사전, 영림사, p974-975, 1998년).
It is a dried fruit of perennial herb Forsythia koreana which belongs to water bureaucrats. It contains ingredients such as forsythol, matairesinoside, oleanolic acid, alkaloid and the like It is known that it is known as the "Information and Communication Sourcing Contest", Younglim Corporation, p974-975, 1998).
이에 본 발명자들은 감초, 황련 또는 연교 추출물을 대상으로 한, 전자 공여능 (electron donating ability) 측정실험, ABTS 라디칼 양이온 소거능 저해활성 측정실험, SOD 디스무타제 유사 활성 법(Superoxide dismutase like assay), Nitric oxide radical 저해활성법 등의 항산화 활성 실험(실험예 1); 피부상재균을 포함한 각종 균주에 대한 항균실험(실험예 2); iNOS, COX-2 발현, LPS에 의해 증가된 iNOS, COX-2 단백질 iNOS mRNA 발현 양에 대한 Western blot assay, Real time PCR 등의 통한 분자생물학적 항염 실험(실험예 3); MTT assay 방법을 통한 세포 생존력 측정실험(실험예 4); 히스카민 분비능 억제 실험, TNF-α 및 IL-8 등의 사이토카인 측정실험 등을 통한 항알러지 활성측정실험(실험예 5)을 통하여 강력학 항산화, 항염, 항균 및 항알러지 활성을 가짐을 확인함으로써 피부노화, 피부염 등에 대한 강력한 억제 효과를 나타내는 피부외용 약학 조성물 및 화장료 조성물의 제공에 유용함을 확인함으로써, 본 발명을 완성하였다.
Therefore, the present inventors have conducted extensive studies on the electron donating ability measurement, the ABTS radical cation-scavenging activity assay, the SOD dismutase-like assay, the nitric oxide antioxidant activity tests such as the radical scavenging activity method (Experimental Example 1); An antibacterial experiment (Experimental Example 2) for various strains including the skin uptake bacteria; iNOS, COX-2 expression, iNOS increased by LPS, Western blot assay for COX-2 protein iNOS mRNA expression level, and real time PCR (Experiment 3); Cell viability measurement test by MTT assay (Experimental Example 4); Anti-inflammatory, antimicrobial, and anti-allergic activity through the experiment of measuring anti-allergic activity (Example 5) by the test for suppressing the secretion of histamine, the cytokine measurement experiment of TNF-α and IL-8 Skin aging, dermatitis and the like, which are effective for the prevention of skin aging and skin irritation. The present invention has been completed based on this finding.
상기 목적을 수행하기 위하여, 본 발명은 감초, 황련 또는 연교 추출물을 유효성분으로 함유하는 피부노화, 또는 피부염 치료 및 개선용 피부외용 약학조성물을 제공한다.In order to accomplish the above object, the present invention provides a dermatological pharmaceutical composition for the treatment and improvement of skin aging or dermatitis, which comprises licorice, chrysanthemum or almond extract as an active ingredient.
본 발명은 감초, 황련 또는 연교 추출물을 유효성분으로 함유하는 피부노화, 또는 피부염 치료 및 개선용 화장료 조성물을 제공한다.
The present invention provides a cosmetic composition for the treatment and improvement of skin aging or dermatitis containing licorice, chrysanthemum or licorice extract as an active ingredient.
본원에서 정의되는 상기 추출물은 정제수를 포함한 물, 주정, 탄소수 1 내지 4의 저급 알콜 또는 이들의 혼합용매, 바람직하게는 물 및 탄소수 1 내지 4의 저급 알콜 혼합용매, 보다 바람직하게는, 50 내지 90% 에탄올 혼합용매에 가용한 추출물을 포함한다.
The extracts as defined herein may be prepared by mixing water, a spirit, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, preferably water and a lower alcohol having 1 to 4 carbon atoms, more preferably 50 to 90 % Ethanol mixed solvent.
상기 피부외용 약학조성물은 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제 제형을 포함한다.The dermatological pharmaceutical composition includes a cream, a gel, a patch, a spray, an ointment, a warning agent, a lotion, a liniment, a pasta agent or a cataplasma formulation.
또한, 상기 화장료 조성물은 헤어토닉, 헤어컨디셔너, 헤어에센스, 헤어로션, 헤어영양로션, 헤어샴푸, 헤어린스, 헤어트리트먼트, 헤어크림, 헤어영양크림, 헤어모이스처크림, 헤어맛사지크림, 헤어왁스, 헤어 에어로졸, 헤어팩, 헤어영양팩, 헤어비누, 헤어클렌징폼, 머릿기름, 모발건조제, 모발보존처리제, 모발염색제, 모발용 웨이브제, 모발탈색제, 헤어겔, 헤어글레이즈, 헤어드레싱어, 헤어래커, 헤어모이스처라이저, 헤어무스 또는 헤어스프레이의 제형을 포함한다.
The cosmetic composition may further comprise at least one selected from the group consisting of hair tonic, hair conditioner, hair essence, hair lotion, hair nourishing lotion, hair shampoo, hair rinse, hair treatment, Hair dye, hair gel, hair glaze, hair dresser, hair lacquer, hair moisturizer, hair dyes, hair dyes, hair dyes, hair dyes, hair dyes, Risers, hair mousses, or hair sprays.
이하, 본 발명의 생약 추출물을 수득하는 방법을 상세히 설명한다.Hereinafter, the method for obtaining the herbal medicine extract of the present invention will be described in detail.
본 발명의 생약 추출물은 감초, 황련 또는 연교를 각각 세척 및 세절하고, 개개 생약 중량의 약 1배 내지 100배(w/w), 바람직하게는 10배 내지 20배(w/w)의 정제수를 포함한 물, 주정, C1내지 C4의 저급 알콜 또는 이들의 혼합용매, 바람직하게는 물 및 탄소수 1 내지 4의 저급 알콜 혼합용매, 보다 바람직하게는, 50 내지 90% 에탄올 혼합용매를 가하여 1시간 내지 72시간, 바람직하게는 2시간 내지 24시간 동안 10℃ 내지 120℃, 바람직하게는 20℃ 내지 60℃에서 1 내지 10회, 바람직하게는 2 내지 5회 냉침추출, 열수추출, 초음파 추출, 환류냉각 추출 등의 추출방법, 바람직하게는 냉침추출법으로 추출한 후 동결건조하여 농축하여 단계를 통하여 본 발명의 감초, 황련 또는 연교 생약 추출물을 수득가능하다.The herbal extract of the present invention is obtained by washing and finely dividing Licorice, Rhodophilus or Salviae respectively and adding purified water of about 1 to 100 times (w / w), preferably 10 to 20 times (w / w) 1 time, including added water, alcohol, C 1 to C 4 lower alcohol or a mixed solvent thereof, preferably water and a lower alcohol mixed solvent, and more preferably, 50 to 90% ethanol, a mixed solvent of 1 to 4 carbon atoms For 1 to 10 times, preferably 2 to 5 times at a temperature of 10 to 120 DEG C, preferably 20 to 60 DEG C for 1 to 72 hours, preferably 2 to 24 hours, by cold extraction, hot water extraction, Extraction with a cold extraction method, preferably freeze extraction method, followed by lyophilization and concentration to obtain the extract of licorice, Chinese persimmon or allium herb medicine of the present invention.
본 발명은 상기 제조방법 및 상기 제조방법으로 수득한 생약 추출물을 유효성분으로 함유하는 피부노화, 또는 피부염 치료 및 개선 효과를 갖는 피부외용 약학 조성물 및 화장료 조성물을 제공한다.The present invention provides an external skin pharmaceutical composition and a cosmetic composition having the skin aging or dermatitis treatment and improvement effect containing the herbal medicine extract obtained by the above production method and the above production method as an effective ingredient.
본 발명자들은 상기 제조방법으로 수득되는 감초, 황련 또는 연교 추출물을 대상으로 한, 전자 공여능 (electron donating ability) 측정실험, ABTS 라디칼 양이온 소거능 저해활성 측정실험, SOD 디스무타제 유사 활성 법(Superoxide dismutase like assay), Nitric oxide radical 저해활성법 등의 항산화 활성 실험(실험예 1); 피부상재균을 포함한 각종 균주에 대한 항균실험(실험예 2); iNOS, COX-2 발현, LPS에 의해 증가된 iNOS, COX-2 단백질 iNOS mRNA 발현 양에 대한 Western blot assay, Real time PCR 등의 통한 분자생물학적 항염 실험(실험예 3); MTT assay 방법을 통한 세포 생존력 측정실험(실험예 4); 히스카민 분비능 억제 실험, TNF-α 및 IL-8 등의 사이토카인 측정실험 등을 통한 항알러지 활성측정실험(실험예 5)을 통하여 강력학 항산화, 항염, 항균 및 항알러지 활성을 가짐을 확인함으로써 피부노화, 피부염 등에 대한 강력한 억제 효과를 나타내는 피부외용 약학 조성물 및 화장료 조성물의 제공에 유용함을 확인하였다.
The inventors of the present invention conducted studies on the electron donating ability measurement, ABTS radical cation-scavenging activity inhibition activity assay, SOD dismutase-like activity assay, assay) and Nitric oxide radical scavenging activity (Experimental Example 1); An antibacterial experiment (Experimental Example 2) for various strains including the skin uptake bacteria; iNOS, COX-2 expression, iNOS increased by LPS, Western blot assay for COX-2 protein iNOS mRNA expression level, and real time PCR (Experiment 3); Cell viability measurement test by MTT assay (Experimental Example 4); Anti-inflammatory, antimicrobial, and anti-allergic activity through the experiment of measuring anti-allergic activity (Example 5) by the test for suppressing the secretion of histamine, the cytokine measurement experiment of TNF-α and IL-8 Skin aging, dermatitis and the like, which are effective for the prevention of skin irritation.
상기 추출물은 조성물 총 중량에 대하여 0.0001 내지 20중량%, 바람직하게는 0.01 내지 10 중량%로 함유하는 것을 특징으로 한다.The extract is characterized by containing 0.0001 to 20% by weight, preferably 0.01 to 10% by weight based on the total weight of the composition.
본 발명의 피부외용 약학조성물은, 조성물 총 중량에 대하여 상기 추출물을 0.1 내지 50 중량%로 포함한다. The dermatological pharmaceutical composition of the present invention contains the above extract in an amount of 0.1 to 50% by weight based on the total weight of the composition.
본 발명의 추출물을 포함하는 피부외용 약학조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The dermatological pharmaceutical composition containing the extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the production of pharmaceutical compositions.
본 발명에 따른 추출물을 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 외용제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 바람직하게는 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용 약학 조성물을 제공한다. 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The pharmaceutical composition containing the extract according to the present invention can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, external preparations such as syrups and aerosols, and sterilized injection solutions according to a conventional method, , Preferably a cream, a gel, a patch, a spray, an ointment, a warning agent, a lotion, a liniment, a pasta or a cataplasma. Examples of carriers, excipients and diluents that may be contained in the composition containing the extract include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 추출물을 함유하는 미백 및 주름 개선용 조성물은 피부에 적용할 수 있는 피부 외용제 제형으로서 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용제 형태의 약학조성물로 제조하여 사용할 수 있으나, 이에 한정하는 것은 아니다.The composition for improving whitening and wrinkles containing the extract of the present invention can be applied to external preparations for skin as external preparations for skin, such as cream, gel, patch, spray, ointment, warning agent, lotion, liniment, pasta or cataplasma Of the present invention can be used as a pharmaceutical composition in the form of external preparation for skin, but the present invention is not limited thereto.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.0001 내지 100㎎/㎏으로, 바람직하게는 0.001 내지 10㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.
The preferred dosage of the extract of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the administration route and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg / kg per day, preferably 0.001 to 10 mg / kg per day. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.
본 발명의 추출물을 포함하는 조성물은 피부노화, 또는 피부염 치료 및 개선 효과를 위한 화장품 및 세안제 등에 다양하게 이용될 수 있다. 본 조성물을 첨가할 수 있는 제품으로는, 예를 들어, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저 등의 화장품류, 세안제, 비누, 트리트먼트, 미용액, 미용팩 등이 있다.The composition containing the extract of the present invention can be variously used for skin aging, cosmetic and cleansing agents for treating and improving dermatitis, and the like. Examples of products to which the present composition can be added include skin lotions, skin softeners, skin toners, astringents, lotions, milky lotions, moisturizing lotions, nutritional lotions, massage creams, nutritional creams, , Cosmetics such as essence, nutrition essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser, cleanser, soap, treatment, essence and cosmetic pack.
본 발명의 화장료는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 조성물을 포함한다.The cosmetic composition of the present invention comprises a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.
수용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 B1, 비타민 B2, 비타민 B6, 피리독신, 염산피리독신, 비타민 B12, 판토텐산, 니코틴산, 니코틴산아미드, 엽산, 비타민 C, 비타민 H 등을 들 수 있으며, 그들의 염 (티아민염산염, 아스코르빈산나트륨염 등)이나 유도체 (아스코르빈산-2-인산나트륨염, 아스코르빈산-2-인산마그네슘염 등)도 본 발명에서 사용할 수 있는 수용성 비타민에 포함된다. 수용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 수득할 수 있다.The water-soluble vitamin is not particularly limited as long as it can be compounded in cosmetics. Preferably, vitamin B, vitamin B2, vitamin B6, pyridoxine, pyridoxine hydrochloride, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, And their salts (thiamine hydrochloride, sodium ascorbate, etc.) or derivatives (sodium ascorbic acid-2-phosphate, magnesium ascorbate-2-phosphate etc.) can also be added to water-soluble vitamins . The water-soluble vitamin can be obtained by a conventional method such as a microorganism conversion method, a purification method from a culture of a microorganism, an enzymatic method, or a chemical synthesis method.
유용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 A, 카로틴, 비타민 D2, 비타민 D3, 비타민 E (d1-알파 토코페롤, d-알파 토코페롤, d-알파 토코페롤) 등을 들 수 있으며, 그들의 유도체 (팔미틴산아스코르빈, 스테아르산아스코르빈, 디팔미틴산아스코르빈, 아세트산dl-알파 토코페롤, 니코틴산dl-알파 토코페롤비타민 E, DL-판토테닐알코올, D-판토테닐알코올, 판토테닐에틸에테르 등) 등도 본 발명에서 사용되는 유용성 비타민에 포함된다. 유용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소 또는 화학 합성법 등의 통상의 방법에 의해 취득할 수 있다.Usable vitamins include vitamins such as vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (d1-alpha tocopherol, d-alpha tocopherol, d-alpha tocopherol) Alpha-tocopherol vitamin E, DL-pantothenyl alcohol, D-pantothenyl alcohol, pantothenyl ethyl laurate, and the derivatives thereof (palmitic acid ascorbin, stearic acid ascorbic acid, dipalmitic acid ascorbin, dl-alpha tocopherol acetate, Ether, etc.) are also included in the usable vitamins used in the present invention. Usability Vitamins can be obtained by a conventional method such as a microorganism conversion method, a purification method from a culture of a microorganism, an enzyme or a chemical synthesis method.
고분자 펩티드로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 콜라겐, 가수 분해 콜라겐, 젤라틴, 엘라스틴, 가수 분해 엘라스틴, 케라틴 등을 들 수 있다. 고분자 펩티드는 미생물의 배양액으로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 정제 취득할 수 있으며, 또는 통상 돼지나 소 등의 진피, 누에의 견섬유 등의 천연물로부터 정제하여 사용할 수 있다.The polymeric peptide may be any compound as long as it can be compounded in cosmetics, and examples thereof include collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, and keratin. The polymeric peptide can be obtained by a conventional method such as purification from a culture broth of a microorganism, an enzymatic method, or a chemical synthesis method, or it can be purified from natural products such as ducks such as pigs and cows and silk fiber of silkworms.
고분자 다당으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 히드록시에틸셀룰로오스, 크산탄검, 히알루론산나트륨, 콘드로이틴 황산 또는 그 염 (나트륨염 등) 등을 들 수 있다. 예를 들어, 콘드로이틴 황산 또는 그 염 등은 통상 포유 동물이나 어류로부터 정제하여 사용할 수 있다.The polymeric polysaccharide may be any compound as long as it can be incorporated in cosmetics, and examples thereof include hydroxyethyl cellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or a salt thereof (sodium salt, etc.). For example, chondroitin sulfate or a salt thereof can be usually purified from mammals or fish.
스핑고 지질로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 세라미드, 피토스핑고신, 스핑고당지질 등을 들 수 있다. 스핑고 지질은 통상 포유류, 어류, 패류, 효모 또는 식물 등으로부터 통상의 방법에 의해 정제하거나 화학 합성법에 의해 취득할 수 있다.Sphingo lipids may be any as long as they can be incorporated into cosmetics, and preferable examples thereof include ceramides, phytosphingosine and sphingoglycolipids. Sphingoid lipids can be purified from ordinary mammals, fish, shellfish, yeast or plants by conventional methods or can be obtained by chemical synthesis.
해초 엑기스로는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 갈조 엑기스, 홍조 엑기스, 녹조 엑기스 등을 들 수 있으며, 또, 이들의 해초 엑기스로부터 정제된 칼라기난, 아르긴산, 아르긴산나트륨, 아르긴산칼륨 등도 본 발명에서 사용되는 해초 엑기스에 포함된다. 해초 엑기스는 해초로부터 통상의 방법에 의해 정제하여 취득할 수 있다.The seaweed extract may be any of those which can be compounded in cosmetics. Preferably, the seaweed extract is selected from the group consisting of algae extract, red pepper extract, green algae extract and the like. Also, the algae extract may be colored guanine, arginic acid, Potassium alginate and the like are also included in the seaweed extract used in the present invention. Seaweed extract can be obtained from seaweed by a conventional method.
본 발명의 화장료에는 상기 필수 성분과 더불어 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합해도 된다.The cosmetic of the present invention may be blended with other essential ingredients, if necessary, in combination with the essential ingredients.
이외에 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.Examples of the compounding ingredients that may be added include organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.
유지 성분으로서는 에스테르계 유지, 탄화수소계 유지, 실리콘계 유지, 불소계 유지, 동물 유지, 식물 유지 등을 들 수 있다.Examples of the oil retaining component include ester-based oil retaining, hydrocarbon-based oil retaining, silicone-based oil retaining, fluoric oil retaining, animal retention and plant retention.
에스테르계 유지로서는 트리2-에틸헥산산글리세릴, 2-에틸헥산산세틸, 미리스틴산이소프로필, 미리스틴산부틸, 팔미틴산이소프로필, 스테아르산에틸, 팔미틴산옥틸, 이소스테아르산이소세틸, 스테아르산부틸, 리놀레산에틸, 리놀레산이소프로필, 올레인산에틸, 미리스틴산이소세틸, 미리스틴산이소스테아릴, 팔미틴산이소스테아릴, 미리스틴산옥틸도데실, 이소스테아르산이소세틸, 세바신산디에틸, 아디핀산디이소프로필, 네오펜탄산이소알킬, 트리(카프릴, 카프린산)글리세릴, 트리2-에틸헥산산트리메틸롤프로판, 트리이소스테아르산트리메틸롤프로판, 테트라2-에틸헥산산펜타엘리슬리톨, 카프릴산세틸, 라우린산데실, 라우린산헥실, 미리스틴산데실, 미리스틴산미리스틸, 미리스틴산세틸, 스테아르산스테아릴, 올레인산데실, 리시노올레인산세틸, 라우린산이소스테아릴, 미리스틴산이소트리데실, 팔미틴산이소세틸, 스테아르산옥틸, 스테아르산이소세틸, 올레인산이소데실, 올레인산옥틸도데실, 리놀레산옥틸도데실, 이소스테아르산이소프로필, 2-에틸헥산산세토스테아릴, 2-에틸헥산산스테아릴, 이소스테아르산헥실, 디옥탄산에틸렌글리콜, 디올레인산에틸렌글리콜, 디카프린산프로필렌글리콜, 디(카프릴,카프린산)프로필렌글리콜, 디카프릴산프로필렌글리콜, 디카프린산네오펜틸글리콜, 디옥탄산네오펜틸글리콜, 트리카프릴산글리세릴, 트리운데실산글리세릴, 트리이소팔미틴산글리세릴, 트리이소스테아르산글리세릴, 네오펜탄산옥틸도데실, 옥탄산이소스테아릴, 이소노난산옥틸, 네오데칸산헥실데실, 네오데칸산옥틸도데실, 이소스테아르산이소세틸, 이소스테아르산이소스테아릴, 이소스테아르산옥틸데실, 폴리글리세린올레인산에스테르, 폴리글리세린이소스테아르산에스테르, 시트르산트리이소세틸, 시트르산트리이소알킬, 시트르산트리이소옥틸, 락트산라우릴, 락트산미리스틸, 락트산세틸, 락트산옥틸데실, 시트르산트리에틸, 시트르산아세틸트리에틸, 시트르산아세틸트리부틸, 시트르산트리옥틸, 말산디이소스테아릴, 히드록시스테아르산 2-에틸헥실, 숙신산디2-에틸헥실, 아디핀산디이소부틸, 세바신산디이소프로필, 세바신산디옥틸, 스테아르산콜레스테릴, 이소스테아르산콜레스테릴, 히드록시스테아르산콜레스테릴, 올레인산콜레스테릴, 올레인산디히드로콜레스테릴, 이소스테아르산피트스테릴, 올레인산피트스테릴, 12-스테알로일히드록시스테아르산이소세틸, 12-스테알로일히드록시스테아르산스테아릴, 12-스테알로일히드록시스테아르산이소스테아릴 등의 에스테르계 등을 들 수 있다.Examples of ester-based fats include glyceryl tri-2-ethylhexanoate, cetyl 2-ethylhexanoate, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, isostearyl isostearate, Butyl isopropyl myristate, isopropyl myristate, isopropyl myristate, isopropyl myristate, isopropyl myristate, isopropyl myristate, butyl, ethyl linoleate, isopropyl linoleate, ethyl oleate, isosilyl myristate, isostearic acid isostearyl, isostearyl palmitate, octyldodecyl myristate, Trimethylol propane, triisostearic acid trimethylol propane, tetra 2-ethylhexanoic acid pentaerythritol tetra (2-ethylhexanoate) , Decyl caprylate, decyl laurate, hexyl laurate, myristate decyl, myristyl myristate, myristine monoethyl stearate, stearyl stearate, decyl oleate, ricinoleic acid tri , Isostearyl stearate, isostearyl stearate, isodecyl stearate, octyldodecyl oleate, octyldodecyl linoleate, isopropyl isostearate, isopropyl stearate, isopropyl stearate, isopropyl stearate, -Hexyl stearate, stearyl ethylhexanoate, stearyl 2-ethylhexanoate, hexyl isostearate, ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicaprate, di (capryl, capric acid) propylene glycol, Propyleneglycol propionate, propyleneglycol propionate, dicaproic acid neopentyl glycol, dioctanoic acid neopentyl glycol, tricarboxylic acid glyceryl, triunsaturated glyceryl, triisopalmitic acid glyceryl, triisostearic acid glyceryl, neopentanoic acid octyldodecyl Octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, Octyldecyl lactate, octyldecyl lactate, octyldecyl lactate, polyglycerin oleic acid ester, polyglycerin isostearic acid ester, triisocetyl citrate, triisobutyl citrate, triisooctyl citrate, lauryl lactate, myristyl lactate, But are not limited to, ethyl, acetyltriethyl citrate, acetyltributyl citrate, trioctyl citrate, diisostearyl malate, 2-ethylhexyl hydroxystearate, di-2-ethylhexyl succinate, diisobutyl adipate, diisopropyl sebacate, But are not limited to, dioctyl sebacate, stearic acid cholesteryl, isostearic acid cholesteryl, hydroxystearic acid cholesteryl, oleic acid cholesteryl, oleic acid dihydrocholesteryl, isostearic acid pitostearyl, Stearoyl hydroxystearic acid isostearyl, 12-stearoyl stearyl hydroxystearate, 12-stearo And monohydroxystearic acid and esters such as sostearyl.
탄화 수소계 유지로서는 스쿠알렌, 유동 파라핀, 알파-올레핀올리고머, 이소파라핀, 세레신, 파라핀, 유동 이소파라핀, 폴리부덴, 마이크로크리스탈린왁스, 와셀린 등의 탄화 수소계 유지 등을 들 수 있다.Examples of the hydrocarbon hydrocarbon-based fats include hydrocarbon fats and oils such as squalene, liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, floating isoparaffin, polybutene, microcrystalline wax and vaseline.
실리콘계 유지로서는 폴리메틸실리콘, 메틸페닐실리콘, 메틸시클로폴리실록산, 옥타메틸폴리실록산, 데카메틸폴리실록산, 도데카메틸시클로실록산, 디메틸실록산ㆍ메틸세틸옥시실록산 공중합체, 디메틸실록산ㆍ메틸스테알록시실록산 공중합체, 알킬 변성 실리콘유, 아미노 변성 실리콘유 등을 들 수 있다.Examples of silicone based oils include polymethyl silicone, methylphenyl silicone, methyl cyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane-methylcetyloxysiloxane copolymer, dimethylsiloxane-methylstarchoxysiloxane copolymer, alkyl Modified silicone oils, and amino-modified silicone oils.
불소계 유지로서는 퍼플루오로폴리에테르 등을 들 수 있다.Examples of the fluorine-based oil include perfluoropolyether and the like.
동물 또는 식물 유지로서는 아보카도유, 아르몬드유, 올리브유, 참깨유, 쌀겨유, 새플라워유, 대두유, 옥수수유, 유채유, 행인(杏仁)유, 팜핵유, 팜유, 피마자유, 해바라기유, 포도종자유, 면실유, 야자유, 쿠쿠이너트유, 소맥배아유, 쌀 배아유, 시아버터, 월견초유, 마커데이미아너트유, 메도홈유, 난황유, 우지(牛脂), 마유, 밍크유, 오렌지라피유, 호호바유, 캔데리러왁스, 카르나바왁스, 액상 라놀린, 경화피마자유 등의 동물 또는 식물 유지를 들 수 있다.Examples of animal or vegetable oils include avocado oil, almond oil, olive oil, sesame oil, rice bran oil, new flower oil, soybean oil, corn oil, rape oil, apricot kernel oil, palm kernel oil, palm oil, castor oil, , Corn oil, palm oil, palm oil, cucumber nut oil, wheat germ oil, rice germ oil, shea butter, coltsfoot colostrum, marker daisy nut oil, mead home oil, egg oil, , Canned wax, carnauba wax, liquid lanolin, hardened castor oil, and the like.
보습제로서는 수용성 저분자 보습제, 지용성 분자 보습제, 수용성 고분자, 지용성 고분자 등을 들 수 있다.Examples of the moisturizing agent include water-soluble low-molecular moisturizing agents, oil-soluble molecular moisturizing agents, water-soluble polymers, and oil-soluble polymers.
수용성 저분자 보습제로서는 세린, 글루타민, 솔비톨, 만니톨, 피롤리돈-카르복실산나트륨, 글리세린, 프로필렌글리콜, 1,3-부틸렌글리콜, 에틸렌글리콜, 폴리에틸렌글리콜B(중합도 n = 2 이상), 폴리프로필렌글리콜(중합도 n = 2 이상), 폴리글리세린B(중합도 n = 2 이상), 락트산, 락트산염 등을 들 수 있다.Examples of the water-soluble low-molecular moisturizing agent include serine, glutamine, sorbitol, mannitol, sodium pyrrolidone-carboxylate, glycerin, propylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol B Glycol (polymerization degree n = 2 or more), polyglycerin B (polymerization degree n = 2 or more), lactic acid, lactic acid salt and the like.
지용성 저분자 보습제로서는 콜레스테롤, 콜레스테롤에스테르 등을 들 수 있다.Examples of the lipid-soluble low-molecular moisturizing agent include cholesterol and cholesterol ester.
수용성 고분자로서는 카르복시비닐폴리머, 폴리아스파라긴산염, 트라가칸트, 크산탄검, 메틸셀룰로오스, 히드록시메틸셀룰로오스, 히드록시에틸셀룰로오스, 히드록시프로필셀룰로오스, 카르복시메틸셀룰로오스, 수용성 키틴, 키토산, 덱스트린 등을 들 수 있다.Examples of the water-soluble polymer include carboxyvinyl polymer, polyaspartic acid, tragacanth, xanthan gum, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, water-soluble chitin, chitosan, dextrin, etc. .
지용성 고분자로서는 폴리비닐피롤리돈ㆍ에이코센 공중합체, 폴리비닐피롤리돈ㆍ헥사데센 공중합체, 니트로셀룰로오스, 덱스트린지방산에스테르, 고분자 실리콘 등을 들 수 있다.Examples of the oil-soluble polymer include polyvinylpyrrolidone / eicosene copolymer, polyvinylpyrrolidone / hexadecene copolymer, nitrocellulose, dextrin fatty acid ester, and polymer silicone.
에몰리엔트제로서는 장쇄아실글루타민산콜레스테릴에스테르, 히드록시스테아르산콜레스테릴, 12-히드록시스테아르산, 스테아르산, 로진산, 라놀린지방산콜레스테릴에스테르 등을 들 수 있다.Examples of the emollients include long chain acyl glutamic acid cholesteryl ester, hydroxystearic acid cholesteryl, 12-hydroxystearic acid, stearic acid, rosin acid and lanolin fatty acid cholesteryl ester.
계면 활성제로서는 비이온성 계면 활성제, 음이온성 계면 활성제, 양이온성 계면 활성제, 양성 계면 활성제 등을 들 수 있다.Examples of the surfactant include nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants.
비이온성 계면 활성제로서는 자기 유화형 모노스테아르산글리세린, 프로필렌글리콜지방산에스테르, 글리세린지방산에스테르, 폴리글리세린지방산에스테르, 솔비탄지방산에스테르, POE (폴리옥시에틸렌)솔비탄지방산에스테르, POE 솔비트지방산에스테르, POE 글리세린지방산에스테르, POE 알킬에테르, POE 지방산에스테르, POE 경화피마자유, POE 피마자유, POEㆍPOP (폴리옥시에틸렌ㆍ폴리옥시프로필렌) 공중합체, POEㆍPOP 알킬에테르, 폴리에테르변성실리콘, 라우린산알카놀아미드, 알킬아민옥시드, 수소첨가대두인지질 등을 들 수 있다.Examples of the nonionic surfactant include self emulsifying monostearate glycerin, propylene glycol fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, sorbitan fatty acid ester, POE (polyoxyethylene) sorbitan fatty acid ester, POE sorbit fatty acid ester, POE (Polyoxyethylene / polyoxypropylene) copolymer, POE.POP alkyl ether, polyether-modified silicone, polyether-modified silicone, polyoxyethylene-polyoxypropylene (POE) Alkanolamides, alkylamine oxides, hydrogenated soybean phospholipids, and the like.
음이온성 계면 활성제로서는 지방산비누, 알파-아실술폰산염, 알킬술폰산염, 알킬알릴술폰산염, 알킬나프탈렌술폰산염, 알킬황산염, POE 알킬에테르황산염, 알킬아미드황산염, 알킬인산염, POE 알킬인산염, 알킬아미드인산염, 알킬로일알킬타우린염, N-아실아미노산염, POE 알킬에테르카르복실산염, 알킬술포숙신산염, 알킬술포아세트산나트륨, 아실화 가수분해 콜라겐펩티드염, 퍼플루오로알킬인산에스테르 등을 들 수 있다.Examples of the anionic surfactant include fatty acid soap, alpha-acylsulfonate, alkylsulfonate, alkylallylsulfonate, alkylnaphthalenesulfonate, alkylsulfate, POE alkylether sulfate, alkylamide sulfate, alkyl phosphate, POE alkyl phosphate, alkylamide phosphate , Alkyloyl taurine salts, N-acyl amino acid salts, POE alkyl ether carboxylates, alkylsulfosuccinates, sodium alkylsulfoacetates, acylated hydrolyzed collagen peptide salts, and perfluoroalkyl phosphate esters .
양이온성 계면 활성제로서는 염화알킬트리메틸암모늄, 염화스테아릴트리메틸암모늄, 브롬화스테아릴트리메틸암모늄, 염화세토스테아릴트리메틸암모늄, 염화디스테아릴디메틸암모늄, 염화스테아릴디메틸벤질암모늄, 브롬화베헤닐트리메틸암모늄, 염화벤잘코늄, 스테아르산디에틸아미노에틸아미드, 스테아르산디메틸아미노프로필아미드, 라놀린 유도체 제 4급 암모늄염 등을 들 수 있다.Examples of the cationic surfactant include alkyl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, stearyl trimethyl ammonium bromide, cetostearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, stearyl dimethyl benzyl ammonium chloride, behenyl trimethyl ammonium chloride, Benzalkonium, diethylaminoethylamide stearate, dimethylaminopropylamide stearate, quaternary ammonium salts of lanolin derivatives, and the like.
양성 계면 활성제로서는 카르복시베타인형, 아미드베타인형, 술포베타인형, 히드록시술포베타인형, 아미드술포베타인형, 포스포베타인형, 아미노카르복실산염형, 이미다졸린 유도체형, 아미드아민형 등의 양성 계면 활성제 등을 들 수 있다.Examples of the amphoteric surfactant include carboxybetaine type, amide betaine type, sulfobetaine type, hydroxysulfobetaine type, amidosulfobetaine type, phosphobetaine type, aminocarboxylate type, imidazoline derivative type and amide amine type Amphoteric surfactants and the like.
유기 및 무기 안료로서는 규산, 무수규산, 규산마그네슘, 탤크, 세리사이트, 마이카, 카올린, 벵갈라, 클레이, 벤토나이트, 티탄피막운모, 옥시염화비스무트, 산화지르코늄, 산화마그네슘, 산화아연, 산화티탄, 산화알루미늄, 황산칼슘, 황산바륨, 황산마그네슘, 탄산칼슘, 탄산마그네슘, 산화철, 군청, 산화크롬, 수산화크롬, 칼라민 및 이들의 복합체등의 무기 안료 ; 폴리아미드, 폴리에스테르, 폴리프로필렌, 폴리스티렌, 폴리우레탄, 비닐수지, 요소수지, 페놀수지, 불소수지, 규소수지, 아크릴수지, 멜라민수지, 에폭시수지, 폴리카보네이트수지, 디비닐벤젠ㆍ스티렌 공중합체, 실크파우더, 셀룰로오스, CI 피그먼트옐로우, CI 피그먼트오렌지 등의 유기 안료 및 이들의 무기 안료와 유기 안료의 복합 안료 등을 들 수 있다.Examples of the organic and inorganic pigments include inorganic pigments such as silicic acid, silicic anhydride, magnesium silicate, talc, sericite, mica, kaolin, Bengala, clay, bentonite, titanium mica, titanium oxide, bismuth chloride, zirconium oxide, magnesium oxide, Inorganic pigments such as calcium sulfate, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, iron oxide, chromium oxide, chromium oxide, chromium hydroxide, But are not limited to, polyamide, polyester, polypropylene, polystyrene, polyurethane, vinyl resin, urea resin, phenol resin, fluororesin, silicon resin, acrylic resin, melamine resin, epoxy resin, polycarbonate resin, Silk powder, cellulose, CI Pigment Yellow, CI Pigment Orange, and composite pigments of inorganic pigments and organic pigments thereof.
유기 분체로서는 스테아르산칼슘 등의 금속비누 ; 세틸린산아연나트륨, 라우릴린산아연, 라우릴린산칼슘 등의 알킬인산금속염 ; N-라우로일-베타-알라닌칼슘, N-라우로일-베타-알라닌아연, N-라우로일글리신칼슘 등의 아실아미노산 다가금속염 ; N-라우로일-타우린칼슘, N-팔미토일-타우린칼슘 등의 아미드술폰산 다가금속염 ; N-엡실론-라우로일-L-리진, N-엡실론-팔미토일리진, N-알파-파리토일올니틴, N-알파-라우로일아르기닌, N-알파-경화우지지방산아실아르기닌 등의 N-아실염기성아미노산 ; N-라우로일글리실글리신 등의 N-아실폴리펩티드 ; 알파-아미노카프릴산, 알파-아미노라우린산 등의 알파-아미노지방산 ; 폴리에틸렌, 폴리프로필렌, 나일론, 폴리메틸메타크릴레이트, 폴리스티렌, 디비닐벤젠ㆍ스티렌 공중합체, 사불화에틸렌 등을 들 수 있다.As the organic powder, metallic soap such as calcium stearate; Metal salts of alkyl phosphates such as sodium zinc cetylate, zinc laurylate and calcium lauryl laurate; Acylamino acid polyvalent metal salts such as N-lauroyl-beta-alanine calcium, N-lauroyl-beta-alanine zinc and N-lauroylglycine calcium; Amidosulfonic acid multivalent metal salts such as N-lauroyl-taurine calcium and N-palmitoyl-taurine calcium; Such as N-epsilon-lauroyl-L-lysine, N-epsilon-palmitoylidene, N-alpha-paratyylnitine, N-alpha-lauroyl arginine, Acyl basic amino acids; N-acylpolypeptides such as N-lauroylglycylglycine; Alpha-amino fatty acids such as alpha-aminocaprylic acid, alpha-aminoaurauric acid, and the like; Polyethylene, polypropylene, nylon, polymethylmethacrylate, polystyrene, divinylbenzene-styrene copolymer, ethylene tetrafluoride, and the like.
자외선 흡수제로서는 파라아미노벤조산, 파라아미노벤조산에틸, 파라아미노벤조산아밀, 파라아미노벤조산옥틸, 살리실산에틸렌글리콜, 살리신산페닐, 살리신산옥틸, 살리신산벤질, 살리신산부틸페닐, 살리신산호모멘틸, 계피산벤질, 파라메톡시계피산-2-에톡시에틸, 파라메톡시계피산옥틸, 디파라메톡시계피산모노-2-에틸헥산글리세릴, 파라메톡시계피산이소프로필, 디이소프로필ㆍ디이소프로필계피산에스테르 혼합물, 우로카닌산, 우로카닌산에틸, 히드록시메톡시벤조페논, 히드록시메톡시벤조페논술폰산 및 그 염, 디히드록시메톡시벤조페논, 디히드록시메톡시벤조페논디술폰산나트륨, 디히드록시벤조페논, 테트라히드록시벤조페논, 4-tert-부틸-4'-메톡시디벤조일메탄, 2,4,6-트리아닐리노-p-(카르보-2'-에틸헥실-1'-옥시)-1,3,5-트리아진, 2-(2-히드록시-5-메틸페닐)벤조트리아졸 등을 들 수 있다.Examples of ultraviolet absorbers include paraaminobenzoic acid, ethyl parnamobenzoate, amyl paranobenzoate, octyl paranobenzoate, ethyleneglycol salicylate, phenyl salicylate, benzyl salicylate, benzyl salicylate, butylphenyl salicylate, homomenthyl salicylate, benzyl cinnamate , Octyl methoxycinnamate, dioctyl methoxycinnamate, mono-2-ethylhexane glyceryl dipyrromethoxycinnamate, isopropyl paratumoxycinnamate, diisopropyl-diisopropyl cinnamate ester mixture, Carninoic acid, ethyl urocanoate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenone sulfonic acid and salts thereof, dihydroxymethoxybenzophenone, sodium dihydroxymethoxybenzophenone disulfonate, dihydroxybenzophenone , Tetrahydroxybenzophenone, 4- tert -butyl-4'-methoxydibenzoylmethane, 2,4,6-trianylino- p- (carbo-2'-ethylhexyl-1'- , 3,5-triazine, 2- (2- And the like can be mentioned hydroxy-5-methylphenyl) benzotriazole.
살균제로서는 히노키티올, 트리클로산, 트리클로로히드록시디페닐에테르, 크로르헥시딘글루콘산염, 페녹시에탄올, 레조르신, 이소프로필메틸페놀, 아줄렌, 살리칠산, 진크필리티온, 염화벤잘코늄, 감광소 301 호, 모노니트로과이어콜나트륨, 운데시렌산 등을 들 수 있다.Examples of the disinfectant include hinokitiol, trichloroacid, trichlorohydroxydiphenyl ether, crohexidine gluconate, phenoxyethanol, resorcin, isopropylmethylphenol, azulene, salicylic acid, zinc filitione, benzalkonium chloride, No. 301, mononitro and eicol sodium, and undecylenic acid.
산화 방지제로서는 부틸히드록시아니솔, 갈릭산프로필, 엘리소르빈산 등을 들 수 있다.Examples of the antioxidant include butylhydroxyanisole, gallic acid propyl, and eicosorbic acid.
pH 조정제로서는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등을 들 수 있다.Examples of the pH adjuster include citric acid, sodium citrate, malic acid, sodium malate, fumaric acid, sodium fumarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogenphosphate and the like.
알코올로서는 세틸알코올 등의 고급 알코올을 들 수 있다.Examples of the alcohol include higher alcohols such as cetyl alcohol.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하지만, 총중량에 대하여 바람직하게는 0.01 - 5 % 중량 백분율, 보다 바람직하게는 0.01 - 3 % 중량 백분율로 배합된다.In addition, any of the above-mentioned components may be blended within the range not to impair the objects and effects of the present invention, but it is preferably 0.01 to 5% by weight based on the total weight, More preferably from 0.01 to 3% by weight.
본 발명의 화장료는 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있다.The cosmetic of the present invention may take the form of a solution, an emulsion, a viscous mixture or the like.
본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및 담체를 포함한다.The ingredients contained in the cosmetic composition of the present invention may contain, in addition to the above-mentioned extracts, the components conventionally used in cosmetic compositions, such as stabilizers, solubilizers, vitamins, pigments and fragrances, And a carrier.
본 발명의 기능성 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 유액, 크림, 화장수, 팩, 파운데이션, 로션, 미용액, 모발화장료 등을 들 수 있다.The functional cosmetic composition of the present invention can be prepared in any formulations conventionally produced in the art, and examples thereof include emulsions, creams, lotions, packs, foundations, lotions, essences, and hair cosmetics.
구체적으로, 본 발명의 화장료 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저의 제형을 포함한다.Specifically, the cosmetic composition of the present invention can be used as a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutrition cream, a moisturizing cream, a hand cream, Packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.In the case of the solution or emulsion of the present invention, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.
When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.
상술한 바와 같이, 본 발명의 감초, 황련 또는 연교 추출물을 대상으로 한, 전자 공여능 (electron donating ability) 측정실험, ABTS 라디칼 양이온 소거능 저해활성 측정실험, SOD 디스무타제 유사 활성 법(Superoxide dismutase like assay), Nitric oxide radical 저해활성법 등의 항산화 활성 실험(실험예 1); 피부상재균을 포함한 각종 균주에 대한 항균실험(실험예 2); iNOS, COX-2 발현, LPS에 의해 증가된 iNOS, COX-2 단백질 iNOS mRNA 발현 양에 대한 Western blot assay, Real time PCR 등의 통한 분자생물학적 항염 실험(실험예 3); MTT assay 방법을 통한 세포 생존력 측정실험(실험예 4); 히스카민 분비능 억제 실험, TNF-α 및 IL-8 등의 사이토카인 측정실험 등을 통한 항알러지 활성측정실험(실험예 5)을 통하여 강력학 항산화, 항염, 항균 및 항알러지 활성을 가짐을 확인함으로써 피부노화, 피부염 등에 대한 강력한 억제 효과를 나타내는 피부외용 약학 조성물 및 화장료 조성물로 사용될 수 있다.
As described above, the present invention provides a method for measuring an electron donating ability, an ABTS radical cation-scavenging activity inhibitory activity test, a SOD dismutase-like activity assay ) And Nitric oxide radical inhibition activity (Experimental Example 1); An antibacterial experiment (Experimental Example 2) for various strains including the skin uptake bacteria; iNOS, COX-2 expression, iNOS increased by LPS, Western blot assay for COX-2 protein iNOS mRNA expression level, and real time PCR (Experiment 3); Cell viability measurement test by MTT assay (Experimental Example 4); Anti-inflammatory, antimicrobial, and anti-allergic activity through the experiment of measuring anti-allergic activity (Example 5) by the test for suppressing the secretion of histamine, the cytokine measurement experiment of TNF-α and IL-8 Skin aging, dermatitis and the like, and can be used as a cosmetic composition.
도 1은 시료의 전자공여능에 미치는 영향을 나타낸 도이고,
도 2는 시료의 ABTS 라디칼 소거능에 미치는 영향을 나타낸 도이고,
도 3은 시료의 SOD-유사 활성에 미치는 영향을 나타낸 도이며,
도 4는 시료의 NO 소거능에 미치는 영향을 측정한 도이고,
도 5는 시료의 항균활성(A:0.5% B:1% C:2% D:3%)을 측정한 도이고,
도 6은 감초 시료의 iNOS 및 COX-2 단백질 발현율에 미치는 영향을 나타낸 도이며,
도 7은 연교 시료의 iNOS 및 COX-2 단백질 발현율에 미치는 영향을 나타낸 도이며,
도 8은 황연 시료의 iNOS 및 COX-2 단백질 발현율에 미치는 영향을 나타낸 도이며,
도 9는 감초 시료의 iNOS 및 COX-2 mRNA 발현율에 미치는 영향을 나타낸 도이며,
도 10은 연교 시료의 iNOS 및 COX-2 mRNA 발현율에 미치는 영향을 나타낸 도이며,
도 11은 황연 시료의 iNOS 및 COX-2 mRNA 발현율에 미치는 영향을 나타낸 도이며,
도 12은 감초 시료의 세포생존능을 나타낸 도이고,
도 13는 연교 시료의 세포생존능을 나타낸 도이고,
도 14은 황연 시료의 세포생존능을 나타낸 도이고,
도 15는 감초 시료의 히스타민 분비능에 미치는 영향을 나타낸 도이고,
도 16는 연교 시료의 히스타민 분비능에 미치는 영향을 나타낸 도이며,
도 17은 황연 시료의 히스타민 분비능에 미치는 영향을 나타낸 나타낸 도이며,
도 18은 감초 시료의 TNF-a 생성능에 미치는 영향을 나타낸 도이고,
도 19는 연교 시료의 TNF-a 생성능에 미치는 영향을 나타낸 도이고,
도 20은 황연 시료의 TNF-a 생성능에 미치는 영향을 나타낸 도이고,
도 21는 감초 시료의 IL-8 생성능에 미치는 영향을 나타낸 도이고,
도 22는 연교 시료의 IL-8 생성능에 미치는 영향을 나타낸 도이고,
도 23은 황연 시료의 IL-8 생성능에 미치는 영향을 나타낸 도이고,
도 24는 로션제의 현미경사진을 나타낸 도이며,
도 25는 로션제의 pH 측정 및 점도측정 결과를 나타낸 도이다.FIG. 1 is a graph showing the effect on the electron donating ability of a sample,
2 shows the effect of the sample on the ABTS radical scavenging ability,
Figure 3 is a graph showing the effect of SOD-like activity of a sample,
FIG. 4 is a graph showing the influence of the sample on NO elimination performance,
FIG. 5 is a graph showing the antimicrobial activity (A: 0.5% B: 1% C: 2
FIG. 6 is a graph showing the effect of licorice samples on iNOS and COX-2 protein expression,
FIG. 7 is a graph showing the effect on the iNOS and COX-2 protein expression rates of the ligated samples,
8 is a graph showing the influence of the chromium samples on iNOS and COX-2 protein expression,
FIG. 9 is a graph showing the effect of licorice samples on iNOS and COX-2 mRNA expression rates,
FIG. 10 is a graph showing the effect on the expression rate of iNOS and COX-2 mRNA in a ligated sample,
FIG. 11 is a graph showing the influence of iNOS and COX-2 mRNA expression ratios of the chrome samples,
12 is a graph showing cell viability of licorice samples,
13 is a graph showing the cell viability of the ligated sample,
FIG. 14 is a graph showing the cell viability of a chrome sample,
Fig. 15 is a graph showing the effect of licorice samples on the histamine releasing ability,
16 is a graph showing the effect on the histamine releasing ability of the ligated sample,
FIG. 17 is a graph showing the effect of the zinc sample on the histamine releasing ability,
18 is a graph showing the effect of the licorice sample on TNF-a production ability,
FIG. 19 is a graph showing the effect of the crosslinked sample on the TNF-a production ability,
20 is a graph showing the effect of the chrome sample on TNF-a production ability,
21 is a graph showing the effect of the licorice sample on the IL-8 production ability,
FIG. 22 is a graph showing the effect on the IL-8 production ability of the ligated sample,
FIG. 23 is a graph showing the effect of the chrome sample on the IL-8 production ability,
Fig. 24 is a microscope photograph of lotion agent,
25 is a diagram showing the pH measurement and the viscosity measurement result of the lotion agent.
이하, 본 발명을 하기 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to the following examples and experimental examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 의해 한정되는 것은 아니다.
However, the following examples and experimental examples are illustrative of the present invention, and the content of the present invention is not limited by the following examples and experimental examples.
실시예 1. 재료 및 시료추출Example 1. Materials and Sample Extraction
본 실험에 사용한 감초, 연교, 황련 각 500g을 옴니허브(www.omnoherb.com)에서 구입하여 70% 에탄올을 시료 중량의 10배 양을 가하여 실온에서 24시간 침지하여 상징액과 침전물을 분리하고 상징액을 회수하는 공정을 3회 반복 추출하였다. 감초, 연교, 황련 상징액을 각각 감압농축 하고 건조하여 감초, 연교, 황련을 각 90.4g, 70.2g, 80.2g의 시료(이하 각각, “GU", "FK" 및 “CC"라 함)를 얻었다.
500 g of licorice, licorice and lichen used in this experiment were purchased from Omni Herb (www.omnoherb.com), and 70% ethanol was added at 10 times the weight of the sample and immersed at room temperature for 24 hours to separate the supernatant and precipitate, The recovering process was repeated three times. (Hereinafter, referred to as "GU", "FK" and "CC", respectively) were obtained by concentrating the dried liquorice, licorice, .
참고예 1. 통계 처리Reference Example 1. Statistics Processing
본 연구는 독립적으로 3회 이상 반복 실시하여 실험한 결과로 모든 실험결과는 평균± 표준편차로 표기하였고, 통계적 유의성은 Student’s t-test로 하였으며, p값이 0.05 미만 일 때 통계적으로 유의하다고 판단하였다.
This study was repeated 3 times or more independently, and all the results were expressed as mean ± SD. Statistical significance was determined by Student's t-test and statistically significant when p value was less than 0.05 .
실험예 1. 항산화 활성 측정Experimental Example 1. Measurement of Antioxidative Activity
상기 실시예에서 수득한 시료의 항산화 활성을 측정하기 위하여 하기 문헌의 방법을 응용하여 실험을 실시하였다.
In order to measure the antioxidative activity of the samples obtained in the above Examples, the following literature methods were applied to conduct experiments.
1-1. 전자 공여능 (electron donating ability) 측정1-1. Measurement of electron donating ability
상기 실시예 시료의 전자공여능을 확인하기 위하여 문헌에 기재된 Blois의 방법을 변형하여 하기와 같이 실험을 수행하였다 [Blois MS. Antioxidant determination by the use of a stable free radical. Nature. 1958;26:1199~1120].In order to confirm the electron donating ability of the sample of the above example, the following experiment was carried out by modifying the Blois method described in literature [Blois MS. Antioxidant determination by the use of a stable free radical. Nature . 1958; 26: 1199-1120].
각 시료용액 100 ㎕에 0.2 mM의 1,1-diphenyl-2-picrylhydrazyl 50 ㎕ 넣고 교반한 후 30분간 방치한 다음 517 ㎚에서 흡광도를 측정하였다.50 μl of 0.2 mM of 1,1-diphenyl-2-picrylhydrazyl was added to 100 μl of each sample solution. After stirring for 30 minutes, absorbance was measured at 517 nm.
1,1-diphenyl-2-picrylhydrazyl (DPPH)는 안정한 자유 라디칼로서, 만일 시료가 항산화 활성을 가지고 있다면 DPPH가 갖고 있는 지질산화에 관여하는 자유 라디칼의 비공유 결합을 소거하여 DPPH의 환원성을 높일 것이고, 보라색의 DPPH가 환원이 많이 될수록 보라색을 잃게 되어 UV 측정시 그 수치도 낮아진다[Amariwicz, R., Naczk, M., Shahidi, F. (2000). Antioxidant activity of various fractions of non-tannic phenolics of canola hulls. J. of Agric Food Chem. 48: 2755-2759.]. 1,1-diphenyl-2-picrylhydrazyl (DPPH) is a stable free radical. If the sample has antioxidant activity, DPPH will reduce the DPPH reduction by eliminating the free radicals involved in lipid oxidation, The higher the amount of purple DPPH is, the more violet the purple is lost, and the lower the UV value, the lower the value is [Amariwicz, R., Naczk, M., Shahidi, F. (2000). Antioxidant activity of various fractions of non-tannic phenolics of canola hulls. J. of Agric Food Chem. 48: 2755-2759.].
본 실험결과, 3가지 샘플의 Eletron donating ability를 측정한 결과, 도 1와 같이 감초, 연교, 황련이 100 ㎍/㎖의 농도에서 각각 59.4%, 69.4%, 73.0%의 효과를 나타냈다. 동일 농도에서 황련이 가장 효능이 우수하였다.
As a result, Eletron donating ability of three samples was 59.4%, 69.4% and 73.0% at the concentration of 100 ㎍ / ㎖, respectively, as shown in FIG. 1. At the same concentration, chrysanthemum was the most effective.
1-2. ABTS 라디칼 양이온 소거능 저해활성 측정 1-2. Measurement of ABTS radical cation-scavenging inhibitory activity
상기 실시예 시료의 ABTS 라디칼 양이온 탈색화(radical cation decolorization) 법에 의한 항산화 효능을 시험하기 위하여 문헌에 개시된 Roberta 등의 방법을 응용하여 하기와 같이 실험하였다. [Roberta, R.E., Pellegrini, N., Anna, P., Ananth, P., Yang, M., Catherine, R.E.,(1999). Antioxidant activity applying an improved ABTS radical cation decolorization assay. J. of Free Radical Biology & Medicine. 26: 1231-1237].
In order to test the antioxidative effect of the sample of the above example by ABTS radical cation decolorization, Roberta et al. [Roberta, RE, Pellegrini, N., Anna, P., Ananth, P., Yang, M., Catherine, RE, (1999). Antioxidant activity was improved by ABTS radical cation decolorization assay. J. of Free Radical Biology & Medicine. 26: 1231-1237].
ABTS radical cation decolorization의 측정은 Roberta 등의 방법에 의해 측정하였다. 즉, 7mM ABTS 5mL와 140mM K2S2O8 88㎕를 ethanol과 약 1:88 비율로 섞어 734nm에서 대조구의 흡광도 값이 0.7±0.002가 되도록 조절한 ABTS solution을 사용하였다. 시료용액 50uL와 ABTS solution 1mL를 혼합하여 30초간 진탕한 후 2.5분간 반응시키고 734nm에서 흡광도를 측정여여 라디칼 소거활성을 계산하였다. ABTS radical cation decolorization was measured by Roberta et al. That is, 5 mL of 7 mM ABTS and 88 μl of 140 mM K 2 S 2 O 8 were mixed with ethanol at a ratio of about 1:88, and the ABTS solution was used so that the absorbance of the control was adjusted to 0.7 ± 0.002 at 734 nm. 50 uL of the sample solution and 1 mL of ABTS solution were mixed, shaken for 30 seconds, reacted for 2.5 minutes, and the absorbance at 734 nm was measured to calculate the radical scavenging activity.
ABTS 법은 다른 간접적인 방법 중에서 가장 많이 사용되는 방법으로 페놀성 화합물을 함유한 시료의 첨가로 인해 ABTS(2,2'-azinobis-(3-ethylben zothiazoline-6-sulfonate)가 산화되어 라디칼 양이온인 ABTS˙+ 가 생성되고 이것의 분해를 측정하여 항산화 활성을 측정한다. ABTS˙+ 는 600 - 750nm의 범위에서 강한 흡수를 보여주며, 페놀성 화합물이 없을 경우 안정하지만, 페놀성 화합물과 같은 수소공여체와는 강렬하게 반응하여 특유의 청록색이 탈색되어 무색의 ABTS로 변환된다. The ABTS method is the most commonly used method among other indirect methods. The addition of a sample containing a phenolic compound oxidizes ABTS (2,2'-azinobis- (3-ethylben zothiazoline-6-sulfonate) ABTS ˙ + is produced and measured for its antioxidant activity by measuring its degradation. ABTS ˙ + shows strong absorption in the range of 600-750 nm, stable when there is no phenolic compound, but hydrogen donor such as phenolic compound And the unique cyan color is discolored and converted into a colorless ABTS.
ABTS radical cation decolorization의 측정한 결과는 도 2와 같다. 감초, 연교, 황련이 50 ㎍/㎖의 농도에서 각각 95.3%, 99.0%, 100%의 높은 활성을 나타내었다. 동일농도에서는 황련이 가장 효능이 우수하였다.
The results of ABTS radical cation decolorization are shown in FIG. Licorice, licorice and Rhodiola showed 95.3%, 99.0% and 100% activity at 50 ㎍ / ㎖, respectively. At the same concentration, chrysanthemum was the most effective.
1-3. SOD 디스무타제 유사 활성 측정 1-3. SOD disutase-like activity measurement
상기 실시예 시료의 SOD 디스무타제 유사 활성 법(Superoxide dismutase like assay)에 의한 항산화 효능을 시험하기 위하여 문헌에 개시된 Marklund의 방법을 응용하여 하기와 같이 실험하였다. [Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur . J. Biochem . 1974;47:469~474l.In order to test the antioxidant efficacy of the sample according to the SOD dismutase like assay, the method of Marklund disclosed in the literature was applied as follows. [Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur . J. Biochem . 1974; 47: 469-4741.
각 시료용액 0.2mL에 Tris-HCl 완충용액 (50mM tris+10mM EDTA, pH 8.5) 2.6mL와 7.2mM pyrogallol 0.2mL 가하여 25℃에서 10분간 반응시킨 후 1M HCl 0.1mL를 가하여 반응을 정지시키고 반응액 중 산화된 pyrogallol의 양을 420nm에서 측정하였다. SOD 유사활성은 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다. To 0.2 mL of each sample solution, 2.6 mL of Tris-HCl buffer (50 mM tris + 10 mM EDTA, pH 8.5) and 0.2 mL of 7.2 mM pyrogallol were added and reacted at 25 ° C for 10 minutes. Then, 0.1 mL of 1M HCl was added to stop the reaction, The amount of oxidized pyrogallol was measured at 420 nm. The SOD - like activity was expressed as the absorbance reduction ratio of the sample solution and the non - added sphere.
항산화 효소 중의 하나인 superoxide dismutase(SOD)는 생체에 매우 유해한 peroxide anion radical(O2 -)과 반응하여 hydrogen peroxide(2O2 - + 2H+ → H2O2 + O2)를 생성하는 효소이다. 이는 산소를 소비하는 모든 생물종에 존재하며, 생체내에서 활성산소 장애에 대한 방어 작용을 하는 대표적인 활성 산소 저해제이다. SOD에 의해 생성된 H2O2는 peroxidase나 catalase에 의하여 무해한 물분자와 산소 분자로 전환시켜 산소 상해로부터 생체를 보호하는 기능으로 알려져 있다. (Pryor WA. Oxy-radicals and related species : their formation, lifetimes, and reactions. Annu. Rev. Physiol. 1986;48:657~667; Greenstock CL. Radiation and aging : free radical damage, biological response and possible antioxidant intervention. Med. Hypotheses. 1993;41(5):473~482)One of the antioxidant enzymes, superoxide dismutase (SOD), is an enzyme that produces hydrogen peroxide (2O 2 - + 2H + → H 2 O 2 + O 2 ) by reacting with a very harmful peroxide anion radical (O 2 - ). It is present in all species that consume oxygen and is a representative active oxygen inhibitor that protects against reactive oxygen defects in vivo. H 2 O 2 produced by SOD is known to be a function that protects living organisms from oxygen injury by converting into harmless water molecules and oxygen molecules by peroxidase or catalase. (Pryor WA) Oxy-radicals and related species: their formation, lifetimes, and reactions. Annu. Rev. Physiol. 1986; 48: 657-667; Greenstock CL. Radiation and aging: free radical damage, biological response and possible antioxidant intervention Med. Hypotheses 1993; 41 (5): 473-482)
이와 같이 생체는 프리 라디칼의 독성으로부터 자신을 보호하기 위해 일련의 산화방어 시스템을 구축하는 진화 과정을 거치면서 현재까지 새로운 환경에 적응해왔다. 이 활성산소를 제거하기 위한 생체 기작으로 superoxide dismutase(SOD), peroxidase(POD), catalase(CAT), glutathione reductase(GR)등의 항산화 효소와 비타민C(ascorbic acid), 비타민 E(tocopherol), 요산 등의 항산화 물질들이 작용하게 된다. 대표적인 활성산소 저해제인 SOD의 경우 체내에 쉽게 흡수되지 못하거나 70℃의 온도에서 쉽게 불활성화 되고 pH10 이상에서는 매우 불안정한 단점을 가지고 있다. 따라서 이러한 단점들을 보완할 수 있는 체내에서 SOD 유사활성 물질의 연구가 필요하다. Thus, living organisms have been adapting to the new environment through the evolutionary process of building a series of oxidation defense systems to protect themselves from free radical toxicity. The antioxidant enzymes such as superoxide dismutase (SOD), peroxidase (POD), catalase (CAT) and glutathione reductase (GR), vitamin C (ascorbic acid), vitamin E (tocopherol) And other antioxidants. SOD, a typical active oxygen inhibitor, has a disadvantage in that it can not be easily absorbed into the body or is easily inactivated at a temperature of 70 ° C and very unstable at
SOD 유사활성을 측정한 결과는 도 3과 같다. 감초, 연교, 황련이 100 ㎍/㎖의 농도에서 각각 27.1%, 86.1%, 93.5%의 높은 활성을 나타내었다. 동일농도에서는 황련이 가장 효능이 우수하였다.
The results of measuring the SOD-like activity are shown in FIG. Licorice, allium, and radish showed high activity of 27.1%, 86.1% and 93.5% at the concentration of 100 ㎍ / ㎖, respectively. At the same concentration, chrysanthemum was the most effective.
1-4. 산화 질소 라디칼 저해 활성 측정1-4. Measurement of nitric oxide radical inhibitory activity
상기 실시예 시료의 Nitric oxide radical 저해활성법에 의한 항산화 효능을 시험하기 위하여 문헌에 개시된 Marcocci등의 방법을 응용하여 하기와 같이 실험하였다. [Marcocci L., Maguire J. J., Droylefaix M. T. and Packer L. : The Nitric Oxide Scavenging Properties of Ginkgo Biloba Extract EGb 761. Biochemical and Biophysical Research Communications. 201, 15, 748-755, 1994]. In order to test the antioxidant activity of the sample according to the nitric oxide radical inhibition method, Marcocci et al. [Marcocci L., Maguire J. J., Droylefaix M. T. and Packer L.: The Nitric Oxide Scavenging Properties of Ginkgo Biloba Extract EGb 761. Biochemical and Biophysical Research Communications. 201, 15, 748-755,1994).
Sodium nitroprusside solutions는 10mM sodium nitroprusside(Lot#BCBH0082V /SIGMA-ALORICH)을 20mM phosphate buffer (pH 7.4)에 녹여 제조하였다. 0.5mL의 시료와 0.5mL의 sodium nitroprusside solutions를 25℃에서 150분간 반응 시켰다. 반응액 1mL과 griess reagent solution을 1 : 1로 반응시켜 540nm에서 흡광도를 측정하였다. Sodium nitroprusside solutions were prepared by dissolving 10 mM sodium nitroprusside (Lot # BCBH0082V / SIGMA-ALORICH) in 20 mM phosphate buffer (pH 7.4). 0.5 mL of sample and 0.5 mL of sodium nitroprusside solution were reacted at 25 ° C for 150 minutes. 1 mL of the reaction solution and griess reagent solution were reacted at 1: 1 and the absorbance was measured at 540 nm.
Nitric oxide는 Reactive Oxygen Species (ROS)의 하나로서 세포독성이 강하며 염증, 암 그리고 다른 병리학적 조건을 유발하는 것으로 알려져 있다. 또한, 다량의 NO는 nitrozation, nitration과 같은 간접적 영향 및 산화반응을 야기하여 유해한 효과를 나타내게 된다. [Sreejayan, N. and Rao, M. NA. : Nitric oxide scavenging by curcuminoids. Journal of Pharmacy and Pharmacology, 49, 105-107, 1997]. Nitric oxide is one of the Reactive Oxygen Species (ROS) that is highly cytotoxic and is known to cause inflammation, cancer and other pathological conditions. In addition, a large amount of NO causes an indirect effect such as nitrozation, nitration, and an oxidation reaction, resulting in a harmful effect. [Sreejayan, N. and Rao, M. NA. : Nitric oxide scavenging by curcuminoids. Journal of Pharmacy and Pharmacology, 49, 105-107, 1997].
본 실험 결과, 도 4에 나타난 바와 같이, 감초, 연교, 황련이 100 ㎍/㎖의 농도에서 각각 21.9%, 61.1%, 17.4%의 활성을 나타내었고 동일 농도에 대조군 Vit 81.9%를 나타내어 연교가 항염증 효능이 가장 우수하게 나타내었다.
As shown in FIG. 4, the activity of licorice, licorice, and radish was 21.9%, 61.1% and 17.4% at a concentration of 100 ㎍ / ㎖, respectively. Inflammatory effects were most excellent.
실험예Experimental Example 2. 항균 활성 측정 2. Antimicrobial activity measurement
상기 실시예에서 수득한 시료의 항균 활성을 측정하기 위하여 하기 문헌의 방법을 응용하여 실험을 실시하였다. In order to measure the antibacterial activity of the sample obtained in the above examples, the following literature test was applied to the experiment.
상기 실시예 시료를 대상으로 Escherichia coli(KTCT 1039), Staphylococcus epidermis(KTCT 1917), candida albicans(KTCT 7965), Staphylococcus aureus(KTCT 1621) 등의 피부상재균을 포함한 Streptcoccus mutans(KTCT 3300), Propionibacterium acnes(KTCT 3314)에 대한 항균 활성 실험을 수행하였다.
Streptococcus mutans (KTCT 3300), Propionibacterium (KTCT 3300) including skin microorganisms such as Escherichia coli (KTCT 1039), Staphylococcus epidermis (KTCT 1917), Candida albicans (KTCT 7965) and Staphylococcus aureus acnes (KTCT 3314).
(1) 균배양(1) Culture of bacteria
피부여드름 개선을 알아보기 위해 피부상재균 Staphylococcus epidermidis , Escherichia coli , Staphylococcus aureus , Candida albicans를 사용하였고 구강청결제의 항균소재로 사용하기 위한 균은 Streptococcus mutans를 사용하였다. 전 배양 및 본 배양을 위한 액체 배지는 S. epidermidis 및 E. coli의 액체배지로는 nutrient broth(NB)를 S. aureus의액체배지로는trypticsoybroth(TSB)를 C. albicans는 YM broth (YMB)배지를 사용하였고 S. epidermidis 및 E. coli의 고체배지로는 nutrient Agar(NA)를 S. aureus의고체배지로는trypticsoyAgar(TSA)를 C. albicans는 YM Agar (YMA)배지를 사용하였다. P. acnes균은 Gifu anaerobic medium(GAM)배지를 액체, 고체 배지 사용하였고 S. mutans는 brain heart infusion (BHI)의 액체, 고체배지를 사용하였다. P. acnes , S. mutans균은 5%, CO2 incubator에서 37℃로 배양하였고, 그 외의 모든 균주는 BOD incubator에서 37℃로 배양하였다.
To investigate the improvement of skin acne, Staphylococcus epidermidis , Escherichia coli , Staphylococcus aureus , Candida albicans Streptococcus mutans was used as an antimicrobial agent for mouthwash. Liquid medium for preculture and main culture was nutrient broth (NB) for S. epidermidis and E. coli , trypticsoybroth (TSB) for S. aureus and C. albicans for YM broth (YMB) (TSA) for S. aureus and YM Agar (YMA) medium for C. albicans were used as the solid medium for S. epidermidis and E. coli , and nutrient agar (NA) for S. epidermidis and E. coli . In P. acnes , liquid and solid medium were used for Gifu anaerobic medium (GAM) medium and S. mutans was used for liquid and solid medium for brain heart infusion (BHI). P. acnes and S. mutans were cultured in 5% CO 2 incubator at 37 ℃, and all other strains were cultured at 37 ℃ in BOD incubator.
(2) Paper disk diffusion측정(2) Paper disk diffusion measurement
항균력 측정은 Paper disk diffusion법으로 측정하였다. 평판 배지에 single colony 배양된 각 균주를 1 백금이를 취해서 액체배지 10mL에서 18~24시간 배양하여 활성화시킨 후, 다시 액체배지 10mL에 균액을 0.1mL 접종하여 3~6시간 본 배양한 후 평판배지 1개당 균수가 약 1×107 cells이 되게 접종하여 멸균 면봉으로 균일하게 도말하였다. 멸균된 filter paper disc (8mm, Whatman, Japan)를 고체 평판배지에 올려놓은 0.5, 1. 2. 3%의 시료를 농도별로 흡수시켜 37℃에서 18~24시간 배양하여 disc 주위의 clear zone (mm)의 직경을 측정하였다.
The antimicrobial activity was measured by paper disk diffusion method. Each strain cultivated in a single colony on a plate medium was inoculated into 10 mL of the liquid medium for 0.1 to 3 mL for 3 to 6 hours, and then cultured in 10 mL of the liquid medium for 18 to 24 hours. The cells were inoculated at a rate of about 1 × 10 7 cells / well and homogeneously plated with a sterilized cotton swab. A 0.5, 1. 2. 3% sample of sterilized filter paper discs (8 mm, Whatman, Japan) loaded on a solid plate medium was absorbed by concentration and incubated at 37 ° C for 18-24 hours to remove the clear zone ) Was measured.
감초, 연교, 황련의 항균효과를 살펴 본 결과 도 5 와 표 1에 나타내었다. 감초추출물은 Streptcoccus mutans , Propionibacterium acnes 균에서 전 농도 clear zone을 확인할 수 있었다. 연교추출물은 전농도 모든 균에서 항균효능이 없었고 황련추출물은 candida albicans , Streptcoccus mutans , Propionibacterium acnes 균에서 전 농도에서 clear zone을 확인할 수 있었다.The antimicrobial effects of licorice, licorice and licorice were examined in Fig. 5 and Table 1. Licorice extract is Streptococcus mutans , Propionibacterium acnes The clear zone of the total concentration was confirmed in the bacteria. The extracts of agaricus extract did not have antimicrobial activity in all bacteria. candida albicans , Streptcoccus mutans , and Propionibacterium acnes .
StrainsSample
Strains
실험예 3. 감초, 황련, 연교의 분자생물학적 항염 실험Experimental Example 3. Molecular biological anti-inflammatory experiment of licorice, licorice and licorice
3-1. 3-1. WesternWestern blotblot assayassay
100mm tissue culture dish에 cell seeding 후 cell의 confluence가 80%때에 DMEM 배지(AYK 59509 / ThermoSCIENTIFIC)를 무혈청 배지인 EMEM배지(51200-038/gibco brl)로 교환한 후 일정시간동안 cell을 안정화 시키고 추출물과 LPS(1/ml ( Lot #043M4033V / SIGMA) 또는 H2O2 500를 처리하여 24시간동안 배양하였다. 그 후 상등액은 제거한 후 PBS로 2회 세척한 후에 scrapper로 cell을 수확한 후에 lysis buffer를 넣어서 세포를 용출시킨다. 수확된 protein은 BSA(bovine serum albumin)으로 작성한 standard curve에 OD값을 대입시켜서 protein량을 보정하였다. 그 후에 coomassie blue(CAT# Description / expedeon InstantBlue)로 염색하여 재보정한 후에 western sample로 사용하였다.After cell seeding on a 100-mm tissue culture dish, DMEM medium (AYK 59509 / ThermoScienTIFIC) was replaced with EMEM medium (51200-038 / gibco brl) for 80% confluence and the cells were stabilized for a certain period of time. And LPS (1 / ml (Lot # 043M4033V / SIGMA) or H 2 O 2 500. After the supernatant was removed, the cells were washed twice with PBS, harvested with a scrapper, The protein was harvested and the amount of protein was corrected by substituting the OD value into a standard curve prepared with BSA (bovine serum albumin), followed by staining with coomassie blue (CAT # Description / expedeon InstantBlue) And then used as a western sample.
SDS-polyacrylamide gel(#161-0416 / BIO-RAD)을 이용하여 electrophoresis한 후에 gel를 떼어내어서 transfer buffer에 10~15분 정도 담근 후 transfer buffer에 스펀지 2장을 깔고 그 위에 filter paper 1장 올려놓는다. 3mm paper와 nitrocellulose filter도 buffer에 살짝 담근다. 양쪽 스펀지와 2mm paper 사이에 nitrocellulose paper 그리고 gel를 잘 밀착시킨 후에 전극을 꽂아서 transfer시킨다. After electrophoresis using SDS-polyacrylamide gel (# 161-0416 / BIO-RAD), remove the gel and immerse in transfer buffer for 10 ~ 15 minutes.
190mA에서 1시간 이상 transfer한 후에 ponceau S(Cat # 161-0156 / BIO-RAD)에 2분 정도 담근 후에 band를 확인한다. PBS로 2회 씻은 후 꺼내서 blocking buffer(Lot # T0713614S)로 overnight시켜 background는 제거시킨다. 2번 씻은 후에 1:1,000으로 1차 antibody를 붙인 후 2차 antibody(mouse- Lot. L0312 / SantaCruzBiotechnology , rabbit- Lot. H2912, goat- Lot. F1212)를 1:1,000 으로 희석하여 반응시킨다. 2차 antibody를 붙인 후, PBS tween(0000298339/LONZA)으로 수차례 세척한 후에 ECL kit(Amersham Pharmacia, England)를 사용하여 film에 옮긴 후, iNOS, COX-2 단백질 발현량을 확인하였다.After transfer for more than 1 hour at 190mA, immerse in ponceau S (Cat # 161-0156 / BIO-RAD) for 2 minutes and check the band. After washing twice with PBS, remove the background with blocking buffer (Lot # T0713614S). After washing twice, the primary antibody is added at a ratio of 1: 1,000, followed by dilution with a secondary antibody (mouse-Lot.L0312 / SantaCruzBiotechnology, rabbit-Lot.H2912, goat-Lot.F1212) at a ratio of 1: 1,000. Secondary antibodies were attached and washed several times with PBS tween (0000298339 / LONZA). After transferring to a film using ECL kit (Amersham Pharmacia, England), the amount of iNOS and COX-2 protein expression was confirmed.
감초, 황련, 연교 에탄올 추출물에 의한 NO 생성 저해 기전을 확인하기 위해 western blot를 실시하여 단백질의 발현량을 측정한 결과는 도 6 내지 8과 같다.In order to confirm the inhibition mechanism of NO production by licorice, chrysanthemum and licorice ethanol extract, western blot was performed to measure the amount of protein expression, and the results are shown in FIGS.
감초와 연교의 iNOS, COX-2 발현결과, LPS에 의해 증가된 iNOS 단백질 발현양이 100㎍/ml에서 감소되었다. band density 비율에 따라 iNOS 단백질 생성이 감초, 연교가 100㎍/ml에서 각 20%, 30% 정도 감소되었다. COX-2 단백질량은 감초, 연교 모두 100㎍/ml에서만 감소함을 보였다. 황련의 iNOS, COX-2 발현결과, LPS에 의해 증가된 iNOS, COX-2 단백질 모두 발현양이 농도 의존적으로 감소되었다. iNOS, COX-2 100㎍/ml에서 각 30%, 70%이상으로 우수한 항염증 효능을 나타내었다. 이를 통해 감초, 연교, 황련 추출물이 iNOS, COX-2 단백질을 저해하고 그 중 황련은 iNOS, COX-2단백질을 높게 저해함으로써 항염증 화장품소재로 활용가능함을 나타내었다.
As a result of iNOS and COX-2 expression of licorice and licorice, the amount of iNOS protein expression increased by LPS was reduced at 100 μg / ml. According to the band density ratio, iNOS protein production was reduced by 20% and 30% at 100 μg / ml for licorice and aconite, respectively. The amount of COX-2 protein was decreased only at 100 μg / ml in both licorice and licorice. As a result of iNOS and COX-2 expression of Huanglian, the expression level of iNOS and COX-2 protein increased by LPS was decreased in a concentration-dependent manner. iNOS, and COX-2 at 100 μg / ml, respectively. These results suggest that licorice, allium, and hwangryeong extract inhibit iNOS and COX-2 protein, and that they can be used as an anti-inflammatory cosmetic material by highly inhibiting iNOS and COX-2 protein.
3-2. Real time PCR3-2. Real time PCR
(1) RNA 분리 Raw 264.7cells(40071 / Dulbecco)에 1㎖ TRIzol-reagent(MFCD00213058 / SIGMA)를 처리하여 total RNA를 분리하였다. 분리한 RNA에 100 ㎕ phenol과 100 ㎕ chloroform/isoamylalcohol(24:1)을 넣고 잘 섞은 후 원심 분리하는 과정을 2번 반복함으로써 상층액을 분리하였다. 0.5㎖ isopropylalcohol을 이용하여 RNA를 침전시킨 후 70% ethanol로 세척하고 자연 건조시켰으며, RNAase free water에서 RNA를 녹인 후 RNase-free DNase를 첨가하고 -70℃에서 저장 보관하였다. (1) RNA isolation Raw 264.7 cells (40071 / Dulbecco) was treated with 1 ml of TRIzol-reagent (MFCD00213058 / SIGMA) to isolate total RNA. 100 μl of phenol and 100 μl of chloroform / isoamylalcohol (24: 1) were added to the separated RNA, and the supernatant was separated by repeating centrifugation twice. RNA was precipitated with 0.5 ml isopropylalcohol, washed with 70% ethanol and air-dried. RNA was dissolved in RNAase-free water, and RNase-free DNase was added and stored at -70 ° C.
(2) Real-time PCR Transcriptor First strand cDNA synthesis kit(Roche, Germany)를 이용하였고 1μg 의 total RNA를 Anchored-oligo(dT)Primer(Lot B456520/Roche Diagnostics. GmbH), DEPC water로 65℃ 10min 반응시킨 후, transcriptor reverse transcriptase, protector RNase inhibitor, Deoxynucleotide Mix(Lot B456520/Roche Diagnostics. GmbH)로 55℃, 30min, 85℃, 5min heating 시킴으로서 반응을 중지시켰다.합성된 cDNA로부터 COX-2, iNOS, β-actin을 증폭시키기 위하여 SYBR Green I(Roche, Germany)를 이용하여 2μl cDNA,5'과 3' primer를 섞고 Thermal cycler(D04BB-6DF36-0B299041969/Roche Diagnostics. GmbH)를 이용하여 Real-time PCR을 실시하였다. PCR에 의해 생성된 산물은 1.2% Agarose gel(Lot 151204/Mbiotech)에서 전기영동을 실시하고 특정 band를 확인하였다. 시료의 투여에 따른 면역관련인자들의 유전자발현 변화를 확인하기 위해 LPS와 시료 처치 24시간 후 RNA를 추출하여 Real-time PCR을 수행하여 분석하였다. Real-time PCR에 사용된 형광물질은 SYBR green I으로, SYBR green I이란 Double strand DNA에 특이적으로 결합하여 발광을 하는 형광물질로 이 특징을 이용해 PCR이 수행되면서 증폭되는 산물에 결합하여 내는 형광으로 측정하는 것이다. Denaturation 과정에서 single strand로 되었을 땐 결합을 하지 않고 있다가 annealing과정에서 primer가 붙고 double strand가 되었을 때 결합하여 발광을 한다. 실험 결과의 분석은 LPS 단독처리한 군을 calibrator로 사용하여 그 값을 normalization하여 상대적으로 정량하여 gene expression change를 수치화하여 나타내었다. 도 9 내지 11에 나타난 바와 같이, 감초와 연교 황련의 iNOS, COX-2 mRNA 발현결과, LPS에 의해 증가된 iNOS mRNA 발현 양이 농도 의존적으로 감소되었고 황련을 제외한 감초와 연교에서 COX-2 mRNA 발현결과, 농도 의존적으로 감소되었다. 이는 western blot의 iNOS, COX-2 단백질 발현의 결과와 일치되는 것으로 3가지 시료 모두 mRNA 단계에서 iNOS, COX-2 유전자 발현을 억제하는 것으로 나타나 항염효능이 우수한 시료로 화장품소재로 활용할 가능성이 있음을 시사한다.
(2) Real-time PCR Transcriptor First strand cDNA synthesis kit (Roche, Germany) was used and 1 μg of total RNA was reacted with anchored-oligo (dT) Primer (Lot B456520 / Roche Diagnostics GmbH) The reaction was terminated by heating with the transcriptor reverse transcriptase, protector RNase inhibitor, and Deoxynucleotide Mix (Lot B456520 / Roche Diagnostics GmbH) for 5 min at 55 ° C for 30 min at 85 ° C. COX-2, iNOS, β -actin was amplified by real-time PCR using 2 μl cDNA, 5 'and 3' primer using SYBR Green I (Roche, Germany) and thermal cycler (D04BB-6DF36-0B299041969 / Roche Diagnostics GmbH) Respectively. The products generated by PCR were electrophoresed on 1.2% agarose gel (Lot 151204 / Mbiotech) to identify specific bands. RNA was extracted and analyzed by real-time PCR after 24 hours of LPS and sample treatment in order to confirm the changes in gene expression of the immune-related factors upon administration of the sample. The fluorescence material used in the real-time PCR is SYBR green I, which is a fluorescent substance that specifically binds to double strand DNA, SYBR green I, and uses this characteristic to detect fluorescence . In the denaturation process, when a single strand is made, it is not bonded, but when it becomes a double strand with a primer in the annealing process, it combines to emit light. The results of the experiment were compared with those of the LPS - treated group as a calibrator, and their values were normalized to quantify the gene expression change quantitatively. As shown in Figs. 9 to 11, iNOS and COX-2 mRNA expression of licorice and allium phloem showed a dose-dependent decrease in the expression of iNOS mRNA, which was increased by LPS, and expression of COX-2 mRNA in licorice and allium The results were reduced in a concentration dependent manner. These results are consistent with the results of western blot iNOS and COX-2 protein expression, indicating that the three samples inhibit iNOS and COX-2 gene expression at the mRNA stage, It suggests.
실험예Experimental Example 4. 세포 생존력 측정 4. Measurement of cell viability
상기 실시예에서 수득한 시료의 세포 생존력을 측정하기 위하여 하기 문헌의 MTT assay 방법을 응용하여 실험을 실시하였다(Han HK, Choi SS, Shin JC< Chung HS(2007) A study on single oral dose toxicity of highly-developed anthocyanin-pigmented rice varieties. J. Kor. Soc. Food Sci. Nutr. 36:527-533).
In order to measure the cell viability of the samples obtained in the above examples, the MTT assay method of the following literature was applied (Han HK, Choi SS, Shin JC <Chung HS highly-developed anthocyanin-pigmented rice varieties, J. Kor. Soc., Food Sci. Nutr., 36: 527-533).
4-1. 세포배양4-1. Cell culture
인간 비만세포주(Human mast cell)인 HMC-1 세포(대구한의대학교 화장품약리학과 김수진교수님 실험실 분양)는 100 U/ml 페니실린, 100 mg/ml, streptomycin 1%, 그리고 10% inactivated fetal bovine serum(FBS)가 추가된 Iscove’s Modified Dulbecco’sMedia (IMDM)배지(SH30228.01/Thermo SCIENTIFIC)를 이용하여 37℃의 5% CO2 조건에서 배양하였다.
HMC-1 cells (human mast cell) were cultured in 100 U / ml penicillin, 100 mg /
4-2. 실험과정4-2. Experimental course
세포 생존율을 확인하기 위하여 적정 세포수 측정은 96 well plate에 5×105cells/ml이 되게 0.2mL 분주한 후 접종한 후 37℃, 5% CO2 incubator에서 24h 배양 후 무혈청배지 0.18mL로 교체한 뒤 SRA-B3를 농도별로 처리하고 24h 배양하였다. 여기에 5mg/mL의 농도로 제조한 MTT(3-4,5-dimethylthiazol-2-yl]-2,5-diphenyl -tetrazolium bromide) 용액 0.02mL를 첨가하여 4시간 배양한 후 배양액을 제거하고, 각 well당 DMSO:Ethanol(1:1)용액 0.15mL를 가하여 30분간 교반한 뒤 ELISA reader로 550nm에서 흡광도를 측정하였다.
To determine the cell viability, 0.2 mL of each well was inoculated into a 96-well plate at the rate of 5 × 10 5 cells / ml. After inoculation, the cells were incubated in a 5% CO 2 incubator at 37 ° C for 24 h, After replacement, SRA-B3 was treated by concentration and cultured for 24 h. 0.02 mL of a solution of MTT (3-4,5-dimethylthiazol-2-yl) -2,5-diphenyl-tetrazolium bromide prepared at a concentration of 5 mg / mL was added thereto, followed by culturing for 4 hours. 0.15 mL of DMSO: Ethanol (1: 1) solution was added to each well, stirred for 30 minutes, and absorbance was measured at 550 nm with an ELISA reader.
상기 실험 결과, 세포독성은 HMC-1에 PMA+A23187을 처리하여 배양했을 때의 세포 생존율인 100%를 기준으로 감초의 처리농도 0.1, 0.5 및 1 mg/ml에서 각 각 100.85±8.42%, 97.13±7.38% 및 82.16±3.06%로 측정되었으며 세포독성이 없는 것으로 나타났다. (도 12 참조)As a result, the cytotoxicity was 100.85 ± 8.42%, 97.13% at the treatment concentrations of 0.1, 0.5 and 1 mg / ml of licorice on the basis of the cell survival rate when HMC-1 was cultured with PMA + A23187 ± 7.38% and 82.16 ± 3.06%, respectively, indicating no cytotoxicity. (See Fig. 12)
세포독성은 HMC-1에 PMA+A23187을 처리하여 배양했을 때의 세포 생존율인 100%를 기준으로 연교의 처리농도 0.1, 0.5 및 1 mg/ml에서 각 각 109.48±9.49%, 100.61±4.87% 및 95.13±6.43%로 측정되었으며 세포독성이 없는 것으로 나타났다.(도 13 참조)
Cytotoxicity was 109.48 ± 9.49%, 100.61 ± 4.87% at treatment concentrations of 0.1, 0.5 and 1 mg / ml, respectively, based on the cell survival rate when HMC-1 was cultured with PMA + A23187 95.13. + -. 6.43% and was not cytotoxic (see FIG. 13).
세포독성은 HMC-1에 PMA+A23187을 처리하여 배양했을 때의 세포 생존율인 100%를 기준으로 황련의 처리농도 0.1, 0.5 및 1 mg/ml에서 각 각 94.43±2.77%, 86.78±4.60% 및 84.13±5.08%로 측정되었으며 세포독성이 없는 것으로 나타났다. (도 14 참조)
Cytotoxicity was 94.43 ± 2.77%, 86.78 ± 4.60% at 0.1, 0.5 and 1 mg / ml, respectively, on the basis of 100% cell survival rate when HMC-1 was cultured with PMA + A23187 84.13 ± 5.08% and was not cytotoxic. (See Fig. 14)
실험예Experimental Example 5 5 항알러지Anti-allergy 실험 Experiment
상기 실시예에서 수득한 시료의 Histamine, cytokine 분비능에 대한 억제활성을 통한 항알러지 활성을 측정하기 위하여 하기 문헌의 방법을 응용하여 실험을 실시하였다.
In order to measure the anti-allergic activity through the inhibitory activity against the secretory activity of histamine and cytokine of the samples obtained in the above examples, the following literature test was applied.
접촉성 피부염을 유발하기 위해 쥐의 등 부위를 제모한 후, 피부의 미세 상처가 치유되도록 24시간 방치하였다. 본 실험에 사용된 DNCB용액은 아세톤과 올리브오일의 3:1로 혼합된 용액에 0.5%와 1%로 희석한 다음 사용되었다. 1%의 DNCB 용액 150㎕를 등부위에 도포하였고 4일 동안 면역반응을 유발한 후 3주 동안 0.5% DNCB 용액 150㎕를 등부위에 도포하여 접촉성 피부염을 유도하였다. 한방 복합추출물은 PBS에 녹인 후 400mg/kg의 용량으로 2주간 경구 투여하였다. 육안 관찰로 피부염 유발 마우스의 피부 변화 상태를 측정할 수 있었다. In order to induce contact dermatitis, the back part of the rats was depilated and left to stand for 24 hours to heal the micro wounds of the skin. The DNCB solution used in this experiment was diluted to 0.5% and 1% in a 3: 1 mixture of acetone and olive oil. 150 [mu] l of 1% DNCB solution was applied on the back, and immunity was induced for 4 days. After 3 weeks, 150 [mu] l of 0.5% DNCB solution was applied on the back to induce contact dermatitis. The herbal extracts were dissolved in PBS and administered orally at a dose of 400 mg / kg for 2 weeks. The visual change of skin condition of dermatitis induced mice was visualized.
실험 종료일에 주사기로 심장에서 채혈한 후 5,000rpm, 4℃에서 3분동안 원심분리하여 혈청을 분리하였다. Balb/c 마우스의 혈청에서의 IgE 농도 및 PMA+A231867로 자극된 HMC-1 cell 에서의 TNF-α, IL-6, IL-8측정은 enzyme-linked immunosorbent assay 방법을 이용하여 측정하였다. 96 well plate에 각 사이토카인에 대한 단클론 항체를 PBS (pH7.4) 로 희석하여 96well plate에 100씩 각 각 코팅한 다음 4℃에서 12시간 동안 방치한다. 이 plate를 0.05% tween이 함유된 PBS로 세정 후 1% BSA, 5% sucrose, 0.05% NaN3를 함유한 PBS로 1시간 동안 blocking한다. 여러 번 세정한 다음 혈청을 첨가한 후 37℃에서 2시간 동안 방치 후, 각 well을 다시 세정하고 biotin이 결합된 2차 항체를 첨가하여 다시 2시간 동안 방치한다. Well을 씻어낸 다음 avidin peroxidase를 첨가하고 37℃에서 30분 동안 방치하여 well을 다시 세정한 다음에 기질인 ABTS 용액을 첨가하고, 발색반응은 ELISA reader를 사용하여 405nm에서 측정하였다.
On the end of the experiment, the blood was collected from the heart with a syringe and centrifuged at 5,000 rpm at 4 ° C for 3 minutes to separate the serum. Serum IgE levels in Balb / c mice and TNF-α, IL-6 and IL-8 in HMC-1 cells stimulated with PMA + A231867 were measured using an enzyme-linked immunosorbent assay. Dilute the monoclonal antibody against each cytokine in PBS (pH 7.4) to a 96-well plate, and coat each 100-well plate on a 96-well plate. The plate is allowed to stand at 4 ° C for 12 hours. The plate is washed with PBS containing 0.05% tween and blocked with PBS containing 1% BSA, 5% sucrose and 0.05% NaN3 for 1 hour. After washing several times, serum is added and incubated at 37 ° C for 2 hours. The wells are washed again, and biotin-conjugated secondary antibody is added and left for another 2 hours. After washing the wells, avidin peroxidase was added and incubated at 37 ° C for 30 min. After washing the wells again, the substrate ABTS solution was added and the color reaction was measured at 405 nm using an ELISA reader.
5-1. 세포배양5-1. Cell culture
인간 비만세포주(Human mast cell)인 HMC-1 세포는 100 U/ml 페니실린, 100 mg/ml, streptomycin 1%, 그리고 10% inactivated fetal bovine serum(FBS)가 추가된 Iscove’s Modified Dulbecco’sMedia (IMDM)배지(SH30228.01/Thermo SCIENTIFIC)를 이용하여 37℃의 5% CO2 조건에서 배양하였다.
HMC-1 cells, a human mast cell, were cultured in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 100 U / ml penicillin, 100 mg /
5-2. 시료준비5-2. Sample Preparation
HMC-1 세포(3 × 105 cells/ml)를 24 well plate에 1시간 동안 CO2 세균배양기에서 안정화한 다음에 0.1, 0.5 및 1 mg/ml의 농도의 황련, 연교 및 감초를 1시간 동안 전처리하였다. 여기에 PMA(MFCD00036736 / SIGMA) (50 nM) + A23187(MFCD00151202 / SIGMA) (1μM)을 처리한 후 8시간 동안 배양한 후, 상층액을 걷어 사이토카인 변화량을 측정하였고, 같은 방법으로 약물을 전처리한 후 PMA(50 nM) + A23187(1μM)을 처리하여 12시간 동안 배양 후 상층액을 걷어 히스타민 정량을 실시하였다.
HMC-1 cells (3 × 10 5 cells / ml) were plated in 24-well plates for 1 hour in CO 2 After stabilization in the bacterial incubator, the phlyls, alum and licorice at concentrations of 0.1, 0.5 and 1 mg / ml were pretreated for 1 hour. After treatment with PMA (MFCD00036736 / SIGMA) (50 nM) + A23187 (MFCD00151202 / SIGMA) (1 μM), the cells were cultured for 8 hours. The supernatant was removed to determine the amount of cytokine change. And then PMA (50 nM) + A23187 (1 μM) was treated, cultured for 12 hours, and the supernatant was counted for histamine release.
5-3. 5-3. 히스카민Hiscamine 분비능Secretory function 억제실험 Inhibition experiment
히스타민 정량 활성화된 HMC-1에서 분비되는 histamine의 양은 histamine assay kit(IBL -America, Inc., Minneapolis, MN, USA)를 사용하여 측정하였다. Histamine quantitation The amount of histamine secreted in activated HMC-1 was measured using a histamine assay kit (IBL-America, Inc., Minneapolis, MN, USA).
간단히 요약하면, 96 well plate에 각 sample 100μl 와 Histamine-Alkaline Phosphate conjugate(IBL -America, Inc., Minneapolis, MN, USA) 100μl 씩 첨가 한 후 40분간 실온에 방치한다. 이 plate를 0.05% tween이 함유된 PBS로 3회 세정한 후 p-Nitrophenyl Phosphate substrate(MFCD00007319 /SIGMA)를 100μl씩 첨가하여 다시 20분간 실온에 방치한다. 20분 후, 3N NaOH가 함유된 Stop solution을 50μl 첨가하여 발색반응을 ELISA reader(Power Wave XS/BIO-TEK)를 사용하여 405 nm에서 측정하였다. Briefly, 100 μl of each sample and 100 μl of Histamine-Alkaline Phosphate conjugate (IBL-America, Inc., Minneapolis, MN, USA) are added to a 96-well plate and left at room temperature for 40 minutes. After washing the plate three times with PBS containing 0.05% tween, 100 μl of p-Nitrophenyl Phosphate substrate (MFCD00007319 / SIGMA) is added and left at room temperature for 20 minutes. After 20 minutes, 50 μl of a stop solution containing 3N NaOH was added, and the color reaction was measured at 405 nm using an ELISA reader (Power Wave XS / BIO-TEK).
본 실험 결과, 도 15에 나타난 바와 같이, HMC-1세포에 다양한 농도의 감초를 (0.1-1 mg/ml) 전처리 후 PMA+A23187로 12시간 자극하였다. 세포에서 분비되는 Histamine의 양은 Histamine assay kit를 이용하여 측정하였다. 실험 결과, PMA+A23187에 의하여 생성이 증가된 Histamine 양은 감초에 의해 농도 의존적으로 억제됨을 확인하였다. 특히 고농도 감초는 약 22.16%의 억제율을 보였다 (0.51 ± 0.005 pg/ml, P <0.05).As shown in FIG. 15, HMC-1 cells were pretreated with various concentrations of licorice (0.1-1 mg / ml) and stimulated with PMA + A23187 for 12 hours. The amount of histamine released from the cells was measured using a Histamine assay kit. As a result of the experiment, it was confirmed that the amount of Histamine increased by PMA + A23187 was dose-dependently inhibited by licorice. Especially, high concentration of licorice showed a suppression rate of about 22.16% (0.51 ± 0.005 pg / ml, P <0.05).
또한, 도 16에 나타난 바와 같이, HMC-1세포에 다양한 농도의 연교를 (0.1-1 mg/ml) 전처리 후 PMA+A23187로 12시간 자극하였다. 세포에서 분비되는 Histamine의 양은 Histamine assay kit를 이용하여 측정하였다. 실험 결과, PMA+A23187에 의하여 생성이 증가된 Histamine 양은 연교에 의해 농도 의존적으로 억제됨을 확인하였다. 특히 고농도 연교는 약 28.53%의 억제율을 보였다 (0.47 ± 0.003 pg/ml, P <0.05).
In addition, as shown in FIG. 16, HMC-1 cells were pretreated with various concentrations of bridges (0.1-1 mg / ml) and stimulated with PMA + A23187 for 12 hours. The amount of histamine released from the cells was measured using a Histamine assay kit. As a result, it was confirmed that the amount of Histamine increased by PMA + A23187 was dose - dependently inhibited by ligand. In particular, the high-dose rate control showed a 28.53% inhibition rate (0.47 ± 0.003 pg / ml, P <0.05).
또한, 도 17에 나타난 바와 같이, Histamine은 다양한 알레르기 초기 반응에 관여하는 주요한 매개물로 잘 알려져 있으며 특히 가려움증을 일으킨다. 황련의 Histamine 분비 조절에 대한 효과를 조사 하였다. HMC-1세포에 다양한 농도의 황련을 (0.1-1 mg/ml) 전처리 후 PMA+A23187로 12시간 자극하였다. 세포에서 분비되는 Histamine의 양은 Histamine assay kit를 이용하여 측정하였다. 실험 결과, PMA+A23187에 의하여 생성이 증가된 Histamine 양은 황련에 의해 농도 의존적으로 억제됨을 확인하였다. 특히 고농도 황련은 약 24.89 %의 억제율을 보였다 (0.49 ± 0.00005 pg/ml, P <0.05).
Also, as shown in FIG. 17, histamine is well known as a major mediator involved in various allergic reactions, and it causes itching. The effects of Rhodiola on Histamine secretion were investigated. HMC-1 cells were stimulated with PMA + A23187 for 12 hours after pretreatment with various concentrations of phthalocyanine (0.1-1 mg / ml). The amount of histamine released from the cells was measured using a Histamine assay kit. As a result of the experiment, it was confirmed that the amount of Histamine increased by PMA + A23187 was inhibited in a concentration dependent manner by the phloem strain. In particular, the high concentration of thrips showed a suppression rate of about 24.89% (0.49 ± 0.00005 pg / ml, P <0.05).
4-4. 사이토카인 측정: 4-4. Cytokine measurement: TNFTNF -α 및 -α and ILIL -8 측정-8 measurement
HMC-1 세포에서 실시한 사이토카인 측정은 96 well plate에 각 사이토카인에 대한 단클론 항체(IBL -America, Inc., Minneapolis, MN, USA)를 PBS (pH 7.4) 로 희석하여 96 well plate에 100 μl씩 각각 코팅한 다음, 4 ℃에서 12시간 동안 방치한다. 이 plate를 0.05% tween이 함유된 PBS로 세정 후 1% BSA, 5% sucrose, 0.05% NaN3를 함유한 PBS(0000298339/LONZA)로 1시간동안 blocking한다. 여러 번 세정한 다음 샘플을 첨가한 후 37℃에서 2시간 동안 방치 후. 각 well을 다시 세정하고 biotin이 결합된 2차 항체(IBL -America, Inc., Minneapolis, MN, USA)를 첨가하여 다시 2시간 동안 방치한다. Well을 씻어낸 다음 avidin peroxidase(MFCD00130587/SIGMA)를 첨가하고 37℃에서 30 분 동안 방치하여 well을 다시 세정한 다음에 기질인 ABTS 용액(SIGMA A1888, SIGMA P5592)을 첨가하고, 발색반응은 ELISA reader(Power Wave XS/BIO-TEK)를 사용하여 405 nm에서 측정하였다. The HMC-1 cells were diluted in PBS (pH 7.4) with a monoclonal antibody (IBL-America, Inc., Minneapolis, MN, USA) And then allowed to stand at 4 DEG C for 12 hours. The plate is washed with PBS containing 0.05% tween and blocked with PBS (0000298339 / LONZA) containing 1% BSA, 5% sucrose, 0.05% NaN 3 for 1 hour. After washing several times, the sample is added and left at 37 ° C for 2 hours. The wells were washed again and incubated with biotin-conjugated secondary antibody (IBL-America, Inc., Minneapolis, MN, USA) for 2 hours. After washing the wells, avidin peroxidase (MFCD00130587 / SIGMA) was added and the wells were washed again at 37 ° C. for 30 minutes. Substrate ABTS solution (SIGMA A1888, SIGMA P5592) was added. (Power Wave XS / BIO-TEK) at 405 nm.
본 실험 결과, 도 18에 나타난 바와 같이, HMC-1 세포에 다양한 농도의 (0.1-1 mg/ml)의 감초를 전처리 후 PMA+A231867로 자극하였다. 세포에서 분비된 TNF-α의 농도는 ELISA방법으로 측정하였다. 실험 결과. 대조군에 비해 PMA+A231867에 의하여 TNF-α의 생성은 증가하였으나(6.47 ± 0.04 ng/ml, P <0.05), 감초에 의하여 농도 의존적으로 억제 하였다. 특히 고농도(1 mg/ml)의 감초는 약 43.4% 의 억제효과를 보였다(3.67 ± 0.03 ng/ml, P < 0.05).
As shown in FIG. 18, HMC-1 cells were pretreated with various concentrations of (0.1-1 mg / ml) licorice and stimulated with PMA + A231867. The concentration of TNF-α secreted from the cells was measured by ELISA. Experiment result. The production of TNF-α was increased by PMA + A231867 (6.47 ± 0.04 ng / ml, P <0.05) compared with the control, but was inhibited by the licorice concentration-dependent. In particular, the high concentration (1 mg / ml) of licorice inhibited about 43.4% (3.67 ± 0.03 ng / ml, P <0.05).
또한, 도 19에 나타난 바와 같이, HMC-1 세포에 다양한 농도의 (0.1-1 mg/ml)의 연교를 전처리 후 PMA+A231867로 자극하였다. 세포에서 분비된 TNF-α의 농도는 ELISA방법으로 측정하였다. 실험 결과. 대조군에 비해 PMA+A231867에 의하여 TNF-α의 생성은 증가하였으나(6.47 ± 0.04 ng/ml, P <0.05), 연교에 의하여 농도 의존적으로 억제 하였다. 특히 고농도(1 mg/ml)의 연교는 약 37.7% 의 억제효과를 보였다(4.03 ± 0.05 ng/ml, P < 0.05). In addition, as shown in Fig. 19, HMC-1 cells were stimulated with PMA + A231867 after pretreatment with various concentrations of (0.1-1 mg / ml). The concentration of TNF-α secreted from the cells was measured by ELISA. Experiment result. The production of TNF-α was increased by PMA + A231867 (6.47 ± 0.04 ng / ml, P <0.05). Especially, the inhibition effect of high concentration (1 mg / ml) was about 37.7% (4.03 ± 0.05 ng / ml, P <0.05).
또한, 도 20에 나타난 바와 같이, TNF-α는 전염증성 인자로 알레르기 초기 반응에 관여하는 주요한 매개물로 잘 알려져 있다. 황련의 TNF-α생성에 미치는 영향을 조사하였다. HMC-1 세포에 다양한 농도의 (0.1-1 mg/ml)의 황련을 전처리 후 PMA+A231867로 자극하였다. 세포에서 분비된 TNF-α의 농도는 ELISA방법으로 측정하였다. 실험 결과. 대조군에 비해 PMA+A231867에 의하여 TNF-α의 생성은 증가하였으나(6.47 ± 0.04 ng/ml, P <0.05), 황련에 의하여 농도 의존적으로 억제 하였다. 특히 고농도(1 mg/ml)의 황련은 약 49.8% 의 억제효과를 보였다(3.25 ± 0.03 ng/ml, P < 0.05). In addition, as shown in Fig. 20, TNF-a is a proinflammatory factor and is well known as a major mediator involved in the early allergic response. The effect of Rhodiola on TNF-α production was investigated. HMC-1 cells were stimulated with PMA + A231867 after pre-treatment with various concentrations of (0.1-1 mg / ml) The concentration of TNF-α secreted from the cells was measured by ELISA. Experiment result. The production of TNF-α was increased by PMA + A231867 (6.47 ± 0.04 ng / ml, P <0.05) compared to the control, In particular, the high concentration (1 mg / ml) of the rhizomes inhibited about 49.8% (3.25 ± 0.03 ng / ml, P <0.05).
또한, 도 21에 나타난 바와 같이, 세포에 다양한 농도의 (0.1-1 mg/ml) 의 감초를 전처리 후 PMA+A231867로 8시간 동안 자극하였다. 세포에서 분비된 IL-8의 생성량은 ELISA 방법으로 측정하였다. 실험 결과. 대조군에 비해 PMA+A231867에 의하여 IL-8의 생성은 증가하였으나 (5.03 ± 0.12 ng/ml, P < 0.05), 감초에 의하여 농도 의존적으로 억제 하였다. 특히 고농도(1 mg/ml) 의 감초는 약 41.4% 의 억제효과를 보였다(2.95 ± 0.03 ng/ml, P < 0.05). In addition, as shown in Fig. 21, the cells were pretreated with various concentrations of (0.1-1 mg / ml) licorice and stimulated with PMA + A231867 for 8 hours. The amount of IL-8 secreted from the cells was measured by ELISA. Experiment result. The production of IL-8 was increased by PMA + A231867 (5.03 ± 0.12 ng / ml, P <0.05) compared to the control group, but was inhibited by the licorice in a concentration-dependent manner. Especially, high dose (1 mg / ml) licorice inhibited about 41.4% (2.95 ± 0.03 ng / ml, P <0.05).
또한, 도 22에 나타난 바와 같이, 세포에 다양한 농도의 (0.1-1 mg/ml) 의 연교를 전처리 후 PMA+A231867로 8시간 동안 자극하였다. 세포에서 분비된 IL-8의 생성량은 ELISA 방법으로 측정하였다. 실험 결과. 대조군에 비해 PMA+A231867에 의하여 IL-8의 생성은 증가하였으나 (5.03 ± 0.12 ng/ml, P < 0.05), 연교에 의하여 농도 의존적으로 억제 하였다. 고농도(1 mg/ml) 의 연교는 약 19.1% 의 억제효과를 보였다(4.07 ± 0.07 ng/ml, P < 0.05).
In addition, as shown in FIG. 22, the cells were pre-treated with various concentrations of (0.1-1 mg / ml) and stimulated with PMA + A231867 for 8 hours. The amount of IL-8 secreted from the cells was measured by ELISA. Experiment result. The production of IL-8 was increased by PMA + A231867 (5.03 ± 0.12 ng / ml, P <0.05) compared to the control group, but was inhibited by the intercalator in a concentration-dependent manner. The inhibitory effect of high concentration (1 mg / ml) was about 19.1% (4.07 ± 0.07 ng / ml, P <0.05).
IL-8은 neutrophils의 migration에 중요한 역할을 하는 것으로 알려져 있다. [ Kim SJ, Lee EJ, Song YS, Jeong HJ, Le KM, Kim HR, Chae HJ, Shin TY, Kim YK, Hong SH, Kim HM. Cheongyol saseuptang inhibits production of TNF-alpha, IL-6 and IL-8 as well as NF-kappa B activation in human mast cells. J Ethnopharmacol. 2005; 97: 83-8; Kim HM, Park YA, Lee EJ, Shin TY. Inhibition of immediate-type allergic reation by Rosa davurica Pall. In a murine model. J Ethnophamacol. 1999; 67: 53-60] IL-8 is known to play an important role in the migration of neutrophils. [Kim, SJ, Lee EJ, Song YS, Jeong HJ, Le KM, Kim HR, Chae HJ, Shin TY, Kim YK, Hong SH, Kim HM. Cheongyol saseuptang inhibits production of TNF-alpha, IL-6 and IL-8 as well as NF-kappa B activation in human mast cells. J Ethnopharmacol. 2005; 97: 83-8; Kim, HM, Park YA, Lee EJ, Shin TY. Inhibition of immediate-type allergic reation by Rosa davurica Pall. In a murine model. J Ethnophamacol. 1999; 67: 53-60]
세포에 다양한 농도의 (0.1-1 mg/ml) 의 황련을 전처리 후 PMA+A231867로 8시간 동안 자극하였다. 세포에서 분비된 IL-8의 생성량은 ELISA 방법으로 측정하였다. 실험 결과 도 23에 나타난 바와 같이, 대조군에 비해 PMA+A231867에 의하여 IL-8의 생성은 증가하였으나 (5.03 ± 0.12 ng/ml, P < 0.05), 황련에 의하여 농도 의존적으로 억제하였다. 특히 고농도(1 mg/ml) 의 황련은 약 43.4% 의 억제효과를 보였다(2.84 ± 0.10 ng/ml, P < 0.05).
Cells were stimulated with PMA + A231867 for 8 h after pretreatment with various concentrations of (0.1-1 mg / ml) The amount of IL-8 secreted from the cells was measured by ELISA. As shown in FIG. 23, the production of IL-8 was increased (5.03 ± 0.12 ng / ml, P <0.05) by PMA + A231867 in comparison with the control group, In particular, the high concentration (1 mg / ml) of Rhodiola showed about 43.4% inhibition (2.84 ± 0.10 ng / ml, P <0.05).
실험예Experimental Example 5. 5. 로션제형Lotion formulation 제조 및 실험 Manufacturing and Experiment
5-1. 로션의 제조5-1. Manufacture of lotions
로션을 제조하기 위해 사용한 원료들은 표 2와 같다. 로션을 제조하기 위해서 Water phase 와 Oil phase를 각각 85℃까지 가열한 후 Homo mixer를 이용하여 2,500rpm 5분간 유화시켜 제조하였다. 45℃까지 냉각시킨 후 추출물을 첨가하고 마지막으로 Silkem 1650 and Phenoxyethanol and DS-Cerix 5를 첨가하고 agi-mixer를 이용하여 1,700rpm 5분간 믹싱하였다. The raw materials used to make the lotion are shown in Table 2. To prepare lotion, water phase and oil phase were heated to 85 ℃ respectively and emulsified for 5 minutes at 2,500 rpm using a homo mixer. After cooling to 45 ° C, the extract was added and finally Silkem 1650 and Phenoxyethanol and DS-
5-2. 로션의 입자사이즈 측정5-2. Particle size measurement of lotion
로션입자를 관찰하기 위하여 현미경(Eclipse 80i/100X, Nicon, Japan)을 이용하여 내상의 입자의 분포를 확인하였다. 현미경 400배 배율로 관찰한 결과, 도 24에서 보듯이 입자 형태가 다양하며, 균일한 분포를 가지며 입자의 분산 또는 분리가 없음을 확인하였다. 최소 입자 크기는 3μm, 최대 입자 크기는 9μm, 평균 입자 크기는 5~6μm로 나타났다.
In order to observe the lotion particles, the distribution of the inner particles was confirmed using a microscope (Eclipse 80i / 100X, Nicon, Japan). As a result of observing at a magnification of 400 times under a microscope, it was confirmed that the particle shape was varied, uniform distribution and no dispersion or separation of particles as shown in FIG. The minimum particle size was 3 μm, the maximum particle size was 9 μm, and the average particle size was 5 to 6 μm.
5-3. 로션의 안정성 테스트(5-3. Lotion stability test ( pHpH , 점도), Viscosity)
로션의 측정은 pH meter(Hanna Co., Romania)사의 pH meter를 이용하여 25℃에 보관한 추출물이 첨가된 O/W형 로션의 pH를 3회 반복 측정한 후 평균을 구하였다. 측정하기 전에 유리전극은 미리 염기성 완충액이나 증류수에 수시간 담그어 두고 pH meter는 전원에 연결하고 10분 이상 두었다가 사용하였다. 검출부는 증류수로 잘 씻어 가볍게 닦아 낸 다음 사용하였다.The lotion was measured by repeatedly measuring the pH of the O / W type lotion containing the extract stored at 25 ° C three times using a pH meter (Hanna Co., Romania), and then the average was determined. Before measurement, the glass electrode was preliminarily immersed in basic buffer or distilled water for several hours, and the pH meter was connected to a power source for more than 10 minutes. The detector was washed with distilled water and gently wiped off.
점도 측정은 Viscometer(Brookfield Co., USA)를 이용하여 측정하였다. 25℃에 보관한 O/W형 로션을 스핀들(spindle) No.4으로 6rpm에서 1분간 측정하였으며, 기포의 영향을 줄이기 위해 제조 시 탈포를 하였고 3회 반복하여 평균값을 얻었으며, 1회 측정 후 3시간 뒤에 다시 측정하여 3주 동안 측정한 값을 나타내었다. 즉 점도 값에 영향을 줄 수 있는 요인을 최소화하여 측정하였다.
Viscosity measurements were made using a Viscometer (Brookfield Co., USA). The O / W type lotion stored at 25 ° C was measured with a spindle No. 4 at 6 rpm for 1 minute. To reduce the effect of bubbles, defoaming was performed at the time of manufacturing and the average value was obtained by repeating 3 times. After 3 hours, the value was measured again for 3 weeks. In other words, the factors influencing the viscosity were minimized.
5-3. 실험결과5-3. Experiment result
5-3-1. pH 측정5-3-1. pH measurement
실온 (25℃), 0℃, 40℃, cycle chamber, sun light(자연광) 및 artificial light(인공광)에서 보관한 로션의 pH를 28일 동안 측정한 결과, 도 25)에 나타난 바와 같이, 40℃에 보관한 로션의 pH가 다른조건에 비해 pH값이 조금 낮게 나타났으나 관찰기간 및 보관온도에 대한 특별한 변화가 없었다. The pH of the lotion stored at room temperature (25 ° C), 0 ° C, 40 ° C, cycle chamber, sunlight (natural light) and artificial light (28 ° day) The pH value of the lotion stored in the broth was slightly lower than that of the other conditions, but there was no specific change in the observation period and the storage temperature.
5-3-2. 점도측정5-3-2. Viscosity measurement
화장품은 외부환경요인 등에 의한 변질, 변색, 변취, 미생물 오염 등이 없어야 한다. 점도는 직접 또는 간접적으로 태양광선이나 주위환경의 온도에 의해 물리화학적으로 품질의 특성이 변할 가능성이 있기 때문에 이를 파악하기 위한 점도측정은 중요하다. 실온(25℃), 0℃, 40℃, cycle chamber, sun light(자연광) 및 artificial light(인공광)에서 보관한 로션의 점도측정을 28일 동안 측정한 결과, 도 25에 나타난 바와 같이, 측정결과 각 온도별 조건에서 28일 동안 큰 변화없이 점도가 안정한 상태를 유지함을 나타내었다.Cosmetics should be free of alteration, discoloration, alteration, microbial contamination, etc. due to external environmental factors. Viscosity measurement is important to understand the viscosity because the quality of the quality may change physically or chemically depending on the temperature of the sunlight or the surrounding environment, directly or indirectly. The viscosity of the lotion stored at room temperature (25 ° C.), 0 ° C., 40 ° C., cycle chamber, sunlight (natural light) and artificial light (artificial light) was measured for 28 days. As shown in FIG. 25, It was shown that the viscosity remained stable without significant change for 28 days under each temperature condition.
본 발명의 추출물을 포함하는 화장료 조성물의 제제의 예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.
Examples of the preparation of the cosmetic composition containing the extract of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically explained.
제조예 1. 유연 화장수(스킨)의 제조Preparation Example 1. Preparation of a skin lotion (skin)
감초 에틸알코올 추출물을 함유한 화장료 중 유연 화장수(스킨)의 제조예를 하기에 나타내었다.An example of production of a soft lotion (skin) in cosmetics containing licorice ethyl alcohol extract is shown below.
제조예Manufacturing example 2. 영양화장수(로션)의 제조 2. Manufacture of nutrition lotion (lotion)
연교 에틸알코올 추출물을 함유한 화장료 중 영양화장수(로션)의 제조예를 하기에 나타내었다.An example of production of a nutritional lotion (lotion) among the cosmetics containing the ethyl alcohol extract of allium is shown below.
제조예Manufacturing example 3. 영양크림의 제조 3. Manufacture of nutritional cream
황련 에틸알코올 추출물을 함유한 화장료 중 영양크림의 제조예를 하기에 나타내었다.An example of preparation of a nutritional cream among the cosmetics containing the ethyl alcohol extract is shown below.
제조예Manufacturing example 4. 에센스의 제조 4. Manufacture of Essence
감초 에틸 알코올 추출물을 함유한 화장료 중 에센스의 제조예를 하기에 나타내었다.An example of the preparation of the essence in cosmetics containing licorice ethyl alcohol extract is shown below.
제조예Manufacturing example 5. 5. 유화형Emulsion type 파운데이션의 제조 Manufacture of foundations
연교 추출물을 함유한 화장료 중 유화형 파운데이션의 제조예를 표 5에 나타내었다.Table 5 shows an example of the production of an emulsified foundation among the cosmetic compositions containing the almond extract.
제조예Manufacturing example 6. 친수성 연고제의 제조 6. Preparation of hydrophilic ointment
제조예Manufacturing example 7. 7. 미강팩의Of rice pack 제조 Produce
Claims (6)
The cosmetic composition according to claim 4, wherein the cosmetic composition is at least one selected from the group consisting of hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair conditioner, hair treatment, Hair wax, hair aerosol, hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair oil, hair drying agent, hair preservative, hair dye, hair wave agent, hair bleaching agent, hair gel, hair glaze, hair dresser, hair Lacquer, hair moisturizer, hair mousse or hair spray.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140024319A KR20150102449A (en) | 2014-02-28 | 2014-02-28 | Composition comprising an extract of crude drug for treating and improving skin-aging or skin trouble |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140024319A KR20150102449A (en) | 2014-02-28 | 2014-02-28 | Composition comprising an extract of crude drug for treating and improving skin-aging or skin trouble |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20150102449A true KR20150102449A (en) | 2015-09-07 |
Family
ID=54243224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140024319A KR20150102449A (en) | 2014-02-28 | 2014-02-28 | Composition comprising an extract of crude drug for treating and improving skin-aging or skin trouble |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20150102449A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180129159A (en) * | 2017-05-25 | 2018-12-05 | 주식회사 하하푸 | How to make pet beauty shampoo |
KR20210074555A (en) * | 2019-12-12 | 2021-06-22 | 주식회사 코리아나화장품 | Cosmetic Composition for Moisturizing Skin and Soothing Skin Comprising Extracts of Angelica Archangelica and Forsythia Suspense Fruits |
-
2014
- 2014-02-28 KR KR1020140024319A patent/KR20150102449A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180129159A (en) * | 2017-05-25 | 2018-12-05 | 주식회사 하하푸 | How to make pet beauty shampoo |
KR20210074555A (en) * | 2019-12-12 | 2021-06-22 | 주식회사 코리아나화장품 | Cosmetic Composition for Moisturizing Skin and Soothing Skin Comprising Extracts of Angelica Archangelica and Forsythia Suspense Fruits |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100771397B1 (en) | Cosmetic composition comprising an extract of dandelion or luteolin isolated therefrom having anti-oxidant activity and anti-inflammatory activity | |
KR101829553B1 (en) | Cosmetic composition comprising mixture extract of Pisum sativum, Scutellaria baicalensis, Ulmus davidiana, Hippophae rhamnoides fruit for improvement of skin damage or skin-protection | |
KR101397961B1 (en) | Composition comprising the extract of complex herb an active ingredient for preventing and alleviating allergic or non-allergic skin disease and the use thereof | |
KR20070115507A (en) | Skin topical composition comprising iris germanica, centella asiatica urbain, matricaria chamomilia, oenothera odorate jacq. and houttuynia cordata thunb. for improvement of a pimpled skin | |
KR101263547B1 (en) | Cosmetic composition comprising green tea seed coater extract having anti-oxidative or anti-inflammatory activity | |
KR101954773B1 (en) | The purification method for effectively isolating abundant active ingredient form larch tree by-products and the composition comprising the same | |
KR20090130584A (en) | Cosmetic composition comprising an extract of mixed herbs having skin whitening and wrinkle improving activity | |
KR100668290B1 (en) | Cosmeceutical compositions comprising a Rumex acetosella L. extract and/or a Rheum coreanum extract with improvement effect of atopic dermatitis | |
KR20150112103A (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
KR101685121B1 (en) | Skin composition comprising the purified extract of fermented chestnut bur showing anti-aging or anti-inflammatory activity | |
KR20150102449A (en) | Composition comprising an extract of crude drug for treating and improving skin-aging or skin trouble | |
KR20210048021A (en) | Antibacterial compositions comprising the citrus aurantium sinensis peel extract, the magnolia officinalis bark extract and polylysine | |
KR102561258B1 (en) | Composition for controlling sebum and improving pore comprising Jasminum Officinale, Salix Alba (willow) bark and Solanum melogena fruit extract | |
KR101501538B1 (en) | Composition for External Application to the Skin Using an Extract of Seeds of Opuntia ficus-indica var. saboten | |
KR100748851B1 (en) | A topical composition comprising extract of ardisia crenata showing anti-inflammatory and anti-irritation activity | |
KR101793104B1 (en) | Cosmetic composition for whitening skin comprising mixed extract of Cudrania tricuspidata leaf and Morus alba leaf as effective component | |
KR101541842B1 (en) | Skin composition comprising the extract of fermented chestnut bur showing skin whitening and anti-aging or anti-inflammatory activity | |
KR102152407B1 (en) | Cosmetic composition containing phycocyanobilin and its derivative derived from spirulina | |
KR101267765B1 (en) | A preparation method for PSE extract of Prunella vulgaris having antioxidative effect and the cosmetic composition comprising the same | |
KR102073837B1 (en) | A specific preparation method for preparing a distilled extract comprising extract of Schisandra chinensis and the composition comprising the same | |
KR20210063048A (en) | Medical composition comprising extract of Padina gymnospora for skin whitening | |
KR101873244B1 (en) | Skin composition comprising the sprouting seed extract of Schisandra chinensis for anti-wrinkle or anti-inflammatory activity | |
KR100614467B1 (en) | Cosmetic composition comprising the extract mixture of euphorbia helioscopia l., paeonia suffruticosa andr. and aloe vera l. having inhibition activity of melanin synthesis | |
KR102305942B1 (en) | Body cosmetics composition comprising vegetable extract and tumeric extract by multiple fermentation steps | |
KR20130073040A (en) | A composition comprising hemistepsin a or b isolated from the extract of hemistepita lyrata bunge for preventing and treating dandruff |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
N231 | Notification of change of applicant | ||
E601 | Decision to refuse application |